S8 rrna-binding protein from the small ribosomal subunit of staphylococcus aureus

ABSTRACT

A  Staphylococcus aureus  S8 native crystalline structure and a  Staphylococcus aureus  S8 mode of binding with rRNA were identified.

TECHNICAL FIELD OF THE INVENTION

The invention relates to the identification of an RNA-binding domain,its mode of binding with a cognate RNA, and methods enabling design andselection of inhibitors of its binding site.

BACKGROUND OF THE INVENTION

With over 36 classes of known anti-ribosomal agents, the bacterialribosome has been exploited for decades as a target for antibioticdrugs. The essentiality, selectivity, and conserved nature of bacterialtranslation continue to make the ribosome one of the most attractivetargets for the discovery of antibacterial agents. The recentelucidation of the crystal structures of the 30S and 50S ribosomalsubunits from Thermus thermophilus (Wimberly et al., (2000) Nature 407,327-339) and Haloarcula matsumorii (Ban et al., (2000) Science 289,905-920), respectively have provided an enormous amount of detailedstructural information regarding RNA and protein structure, RNA-proteininteractions, and ribosome assembly. In addition, these revolutionarydiscoveries have provided a structural basis for understanding themechanistic processes of translation and the action of antibiotics, andmay also allow for the de novo design of new antibacterial drugs thattarget the translation machinery.

Ribosomal protein S8 is an excellent target for the discovery of newantibacterials. In addition to being absolutely required for the properassembly of the 30S ribosomal subunit in E. coli, the invention providethat S8 in S. pneumoniae is essential for bacterial growth. Moreover,alterations in S8-rRNA affinity can be correlated with growth defectsthat result from the expression of the same mutations in E. coli(Gregory and Zimmermann, (1986), Nucleic Acids Research 14, 5761-76).Ribosomal protein S8 is also a broad-spectrum target, as it is predictedto be very well conserved among bacterial species, see Table 1. Althoughthere is a human ribosomal protein S8, it is significantly divergent andnot thought to be a functional homolog of the bacterial S8. In addition,there does not appear to be any helix 21 homology in eukaryotic 18SrRNA.

Ribosomal protein S8 is a primary rRNA-binding protein that bindsdirectly to a central region of bacterial 16S rRNA called Helix 21.Since S8 is required for the co-operative binding of all 30S proteins,it is essential for the proper assembly of the small ribosomal subunit(Held et al., (1974) J. Biol. Chem 249, 3101-3111). Indeed, mutationswithin the protein have been shown to result in ribosome assembly indefects in E. coli (Geyl et al. (1977) Mol Gen Genet. 29, 331-6). Thebinding site of S8 within Helix 21 rRNA has been extensivelycharacterised in E. coli, and consists of two helical segmentsinterrupted by a very highly conserved core element of irregularstructure that spans nucleotides 595-598 and 640-644 of 16S rRNA. Anunusual feature of this core element, which has been elucidated by NMRstudies (Kalurachchi et al., (1 997) Proc. Natl Acad. Sci USA 94,2139-2144), is the existence of a base triple element betweennucleotides A595 and the A596/U644 base pair in the E. coli rRNA. Thedeletion of A595 severely impairs the binding of E. coli S8 (Mougel etal., (1993) Eur J. Biochem. 215, 787-792), indicating that thisnucleotide is critical for RNA-protein recognition. Interestingly, thisbase triple is predicted by comparative phylogenetic evidence to benearly universally-conserved in prokaryotes (Gutell (1993), NucleicAcids Res. 21, 3051-3054).

While the S8-RNA interactions have been extensively characterized in E.coli, and the crystal structures of both B. stearothermophilus and T.Thermophilus S8 have been solved, prior to this invention very littlewas known regarding the structure and RNA-binding activities ofribosomal proteins from a pathogenic bacterial species. This problem issolved by the instant invention that provides cloned, expressed, andpurified Staphylococcus aureus ribosomal protein S8, and RNA-bindingstudies showing a specific interaction between S8 and S. aureus or E.coli helix 21 RNAs. Mutagenesis studies also provided herein havedefined nucleotides in the core RNA element from S. aureus that areessential for recognition by S8 and suggest a conservation of thestructure of helix 21 in this organism. Also provided herein is acrystal structure of the native S8 protein from S. aureus to 1.56 Åresolution, and superimposition of this structure into the 30S ribosomalsubunit structure of T. thermophilus has provided regions of contactwith a cognate rRNA. Characterisation of S. aureus S8, taken togetherwith a recent published crystal structure of the 30S ribosomal subunit(Wimberly et al., (2000) Nature 407, 327-339) advances understanding ofbacterial ribosome architecture and allows for rational design ofbroad-spectrum antibiotics that target the translational apparatus.

The instant invention further provides a crystal structure of theprotein S8 from the small ribosomal subunit of Staphylococcus aureus inits native state. A preferred structure shows that S8 presents twosurfaces that are suited to bind a cognate rRNA. On of them is a α-helixthat binds into the major groove of the double stranded rRNA. A secondsurface is one in which conserved residues are located and are criticalfor binding to a cognate rRNA. S8 interacts with rRNA through thissecond surface by an interaction that can be described as “riding” overthe double helix. Given the significant role of S8 in organising andbinding rRNA for proper ribosomal function and therefore proper proteinsynthesis, targeting either interaction between S8 and rRNA fordisruption with small molecules could result in an effectiveantimicrobial.

SUMMARY OF THE INVENTION

In one aspect, the present invention relates to an S8 protein that isderived from Staphylococcus aureus and comprising a protein having theamino acid sequence shown in SEQ ID No. 1, and coordinates of Table 2 inan essentially pure native form or a homolog thereof.

In another aspect, the present invention provides a crystalline form ofthe S. aureus S8 rRNA-binding site as derived from models of S8 dockedonto rRNA comprising coordinates of Table 2.

In yet another aspect, the invention provides structural coordinates ofresidues in a binding site responsible for binding of a rRNA.

In yet another aspect, the invention provides structural coordinates ofa rRNA-binding-amino acid residues responsible for a function of S8 orinvolved in binding S8. The invention further provides a method foridentifying inhibitors of an S8-rRNA interaction, which method comprisesthe steps of: providing coordinates of an S8 structure of the inventionto a computerized modeling system; identifying compounds that will bindto the binding site; and screening the compounds identified for S8-rRNAbinding inhibitory bio-activity.

Another aspect of this invention includes machine-readable media encodedwith data representing the coordinates of the three-dimensionalstructure of the S8 crystal structure alone or in complex with RNAand/or DNA.

In another aspect of the invention provides a composition comprising aS8 rRNA-binding protein from a small ribosomal subunit of Staphylococcusaureus in crystalline form.

In a further aspect of the invention provides S8 protein derived fromStaphylococcus aureus and comprising a protein having the coordinates ofTable 2 in an essentially pure native form or a homolog thereof. Stillfurther, an aspect of the invention provides a rRNA-binding mode of theprotein S8 that is derived from Staphylococcus aureus and comprising aprotein having the coordinates of Table 2. In yet another aspect, theinvention provides a rRNA-binding function wherein said S8 protein hasan rRNA-binding site formed by the amino acids 5-19 forming theN-terminal α-helix with nucleotides A820-A885, and the surface of S8lined by residues 4-6, 30-32, 56-57, 82-92, 107-111, and 122-125 thatinteract with nucleotides A587-A758. Another aspect of the inventionprovides for a heavy atom derivative of a Staphylococcus aureus S8protein crystal wherein a rRNA-binding function comprises a proteinhaving the coordinates represented in FIGS. 1 and 7 to 14 and listed inTable 2.

In yet another aspect, the invention provides a process of identifyingan inhibitor compound capable of inhibiting the rRNA-binding activity ofa Staphylococcus aureus S8, said process comprising:

-   -   introducing into a suitable computer program information        defining an rRNA-binding site conformation of a S8 inhibitor        complex molecule comprising a conformation defined by the        coordinates of the structures shown in FIGS. 1 and 7 to 14 and        listed in Table 2 wherein said program displays the        three-dimensional structure thereof;    -   creating a three dimensional structure of a test compound in        said computer program;    -   displaying and superimposing the model of said test compound on        the model of said rRNA-binding site;    -   assessing whether said test compound model fits spatially into        the rRNA-binding site;    -   incorporating said test compound in a biological rRNA-binding        assay for a activity characterized by said rRNA-binding site;        and    -   determining whether said test compound inhibits binding activity        in said assay.

In yet another aspect, the invention provides a process of identifyingan inhibitor compound capable of inhibiting rRNA-binding activity of aStaphylococcus aureus S8 according to claim 2, said process comprising:

-   -   carrying out an in vitro assay by introducing said compound in a        biological rRNA-binding assay according to claim 2 and    -   determining whether said test compound inhibits the ribosomal        enzymatic activity or the rRNA-binding function in said assay.

In yet another aspect, the invention provides a product of the processof that is a peptide, peptidomimetic or synthetic molecule and is usefulfor inhibiting S8-rRNA binding in treatment of bacterial infections in amammal. In another aspect, the invention provides a product that is acompetitive or non-competitive inhibitor of a Staphylococcus aureusS8-rRNA binding activity.

In yet another aspect, the invention provides a process for determininga crystal structure form using structural coordinates of aStaphylococcus aureus S8 crystal or portions thereof, to determine acrystal form of a mutant, homologue or co-complex of said rRNA-bindingfunction by molecular replacement.

In another aspect, the invention provides a process designing drugsuseful for inhibiting Staphylococcus aureus S8 activity using atomiccoordinates of a Staphylococcus aureus S8 to computationally evaluate achemical entity for associating with a rRNA-binding site of aStaphylococcus aureus S8.

In yet another aspect, the invention provides a composition comprising aS8 rRNA-binding protein from the small ribosomal subunit ofStaphylococcus aureus in orthorhombic crystalline form having a spacegroup of P2₁2₁2₁.

A preferred aspect of the invention provides a composition wherein thecrystalline form has lattice constants of a=42.1 Å, b=55.9 Å, c=61.3 Å,α=90.0°, β=90.0°, γ=90.0°.

Another preferred aspect of the invention provides a composition whereina crystalline form contains one Staphylococcus aureus S8 molecule in aasymmetric unit.

In yet another aspect, of the invention provides a S8 proteincomposition wherein a S8 protein has an active site cavity formed by theamino acids S107, T108, S109, and E126. S8 protein composition ischaracterised by the coordinates selected from the group consisting ofthe coordinates of FIGS. 1 and 7 to 14 and Table 2.

Other aspects and advantages of the present invention are describedfurther in the following detailed description of the preferredembodiments thereof.

DESCRIPTION OF THE FIGURES

FIG. 1 provides a representation of a secondary structural elementcrystal structure of a native S8 form S. aureus. The figures (a) and (b)depict views of S8 related by a rotation of 90° around a vertical axis.The ribbons represent α-helices and the arrows represent 5-sheets.

FIG. 2 provides the purification of S. aureus ribosomal protein S8. Lane1, markers (3.5, 6, 14.4, 21.5, 31, 36.5, 55, 66, 97, 116, 200 kDa,bottom to top, respectively); lane 2, uninduced cell pellet; lane 3,induced cell pellet; lane 4, total cell lysate; lane 5, soluble celllysate; lane 6, solubilized cellpellet; lane 7, purified S8 protein.

FIG. 3 provides a filter-binding of S. aureus ribosomal protein S8 to wtand ΔA603 H21 RNA, 32P-RNAs were incubated with increasing amounts of S.aureus S8 on ice for 15 minutes, and then filtered and washed. Maximalbinding was normalized to 100% in this experiment.

FIG. 4 provides sequence and predicted secondary strucuture of S. aureushelix 21 rRNA (nts 596-659)

FIG. 5 provides a diagrammatic representation of a S8-rRNA scintillationproximity assay.

FIG. 6. Scintillation proximity assay development. (a) SPA signal due tothe biotinylated S8 interaction is detected when RNA and protein areincubated together. (b) The SPA signal is specific and representsbiologically-relevant interactions between S8 and rRNA.

FIG. 7 provides a representation of critical residues involved in rRNAbinding and their position relative to secondary structural elements ina crystal structure of native S8 form S. aureus. The two Figures (a) and(b) depict orthogonal view of the S8 protein.

FIG. 8 provides a representation of the model of S8 from S. aureus boundto rRNA via its “lower” or N-terminal surface. In the model, the rRNA isfrom a small ribosomal particle of T. thermophilus, S. aureus S8 wassuperimposed on a corresponding S8 from T thermophilus.

FIG. 9 provides a representation of a model of S8 from S. aureus boundto rRNA via the N-terminal α-helix. In the model, the helix binds to amajor groove of a double stranded rRNA. The rRNA used in the model isfrom a small ribosomal particle of T. thermophilus, The figures (a) and(b) depict views related by a rotation of 90° around a vertical axis.

FIG. 10 provides a representation of a model of S8 from S. aureus boundto rRNA in an intact ribosomal particle. The model was created bysuperimposing a S. aureus S8 onto a homologous S8 in a T. thermophilus30S ribosomal particle structure.

FIG. 11 provides a representation of a molecular surface of S8 from S.aureus. In the model, two surfaces come in contact with the rRNA, theyare distinctly colored: the darker surface corresponds to the N-terminalhelix, and the light gray corresponds to the surface located at theN-terminal side of the molecule.

FIG. 12 provides a representation of a relative position of S8 (arrow)in a ribosomal particle (rRNA also indicated by arrows) as it is shownin the structure of a 30S ribosomal particle of T. thermophilus, wherethree tRNA molecules are bound. S. aureus S8 is expected to bind at thesame relative position in the S. aureus ribosome. The Figures (a) and(b) are related by a 180° rotation about the vertical axis.

FIG. 13 provides a Model of T. thermophilus helix 21 rRNA binding to“underside” of S. aureus S8. S8 residues S107, T108, S109, and E126 makecontacts with helix 21 nts A642, C643, and G644 (the highly-conservedbase triple).

FIG. 14 provides a surface representation of N-terminal region of S.aureus S8. (a) N-terminus (colored in light gray) is predicted to bindto rRNA in T. thermophilus 30S ribosomal subunit. (b) The surfaceelectrostatic potential (dark gray is positive, light gray is negative,hydrophobic is white) is depicted.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides a S8 from Staphylococcus aureuscrystalline structure of the native enzyme.

S8 Protein From Staphylococcus aureus Crystalline Three-DimensionalStructure.

Overall Structure

The crystal structures of S8 from Staphylococcus aureus in its nativeform has been determined and refined to 1.50 Å resolution. The finalmodel includes residues 4-132 and a total of 281 water molecules as inFIG. 1. The polypeptide chain has an α+β fold divided in a somewhatdefined two halves of the molecule: two α-helices and three β-strandsform the N-terminal half of the molecule, and the C-terminal half isformed by a small helix and three short, anti-parallel strands. The N—and the C-terminus of molecule are located on opposite sides of the S8molecule and the loop that connects the N-and C-terminal halves of themolecule protrudes into the solvent on the same side of the molecule asthe C-terminus and opposite to the largest surface used by S8 to bindthe rRNA.

rRNA Binding

Superposition of a S. aureus S8 onto a S8 of the S30 ribosomal subunitof T thermophylus (1FJG) indicates that there are two regions ofinteraction with the rRNA: the N-terminal helix formed by residues 5-19inserts into a major groove of a double helix formed by nucleotidesA820-A885. The second interacting surface is formed by residues 4-6,30-32, 56-57, 82-92, 107-111, and 122-125 on the N-terminus side of amolecule that rides on a double helix formed by nucleotides A587-A758.Either of these two contact surfaces could be targets for smallmolecules that disrupt the interaction; which by affecting S8-rRNAinteractions, ribosomal function would be impaired to the extent ofbeing lethal for a bacterum.

Table 2 provides atomic coordinates of native crystal structures of S8from S. aureus. The amino acid sequence of S8 from S. aureus is providedin SEQ ID No. 1. Small variations in the atomic coordinates shown inTable 2 will occur such as upon refinement of a crystal structure from adifferent crystal form that will result in a new set of coordinates. Thedeviation on Cα atoms from the present coordinate set is not expected tosubstantially exceed a rms of 2.5 Å. Similarly, bond angles and bondlengths will usually vary within a small range.(Engh, R. A., and Huber,R. (1991) Acta Crystallogr. A47, 392400.), however, the inter-atomicinteractions in Table 2 will remain constant, within the experimentalerror, as will the relative conformation and orientation or positioningof residues in the rRNA-binding site.

Mutants and Derivatives

The invention further provides homologues, co-complexes, mutants andderivatives of the S8 crystal structure of the invention.

The term “homologue” means a protein having at least 30% amino acidsequence identity with a functional domain of S8. Preferably thepercentage identity will be 40, or 50%, more preferably 60 or 70% andmost preferably 80 or 90%. A 95% identity is most particularlypreferred.

The term “co-complex” means the S8 or a mutant or homologue of the S8 incovalent or non-covalent association with a chemical entity or compound.

The term “mutant” refers to the S8 polypeptide, i.e., a polypeptidedisplaying the biological activity of wild-type S8 activity,characterized by the replacement of at least one active-site amino acidfrom the wild-type sequence. Such a mutant may be prepared, for example,by expression of the S8 rRNA-binding protein cDNA previously altered inits coding sequence by oligonucleotide-directed mutagenesis.

S8 mutants may also be generated by site-specific incorporation ofunnatural amino acids into the S8 protein using the general biosyntheticmethod of C. J. Noren et al, Science, 244:182-188 (1989). In thismethod, the codon encoding the amino acid of interest in wild-type S8 isreplaced by a “blank” nonsense codon, TAG, usingoligonucleotide-directed mutagenesis. A suppressor directed against thiscodon is then chemically aminoacylated in vitro with the desiredunnatural amino acid. The aminoacylated residue is then added to an invitro translation system to yield a mutant S8 protein with thesite-specific incorporated unnatural amino acid.

Selenocysteine or selenomethionine may be incorporated into wild-type ormutant S8 protein by expression of S8-encoding cDNAs in auxotrophic E.coli strains (W. A. Hendrickson et al, EMBO J., 9 (5): 1665-1672 (1990))or a normal strain grown in a medium supplemented with appropriatenutrients that will prevent endogenous synthesis of methionine. Ineither of these methods, the wild-type or mutated undecaprenylpyrophosphate synthase cDNA may be expressed in a host organism on agrowth medium depleted of either natural cysteine or methionine (orboth) but enriched in selenocysteine or selenomethionine (or both).

The term “heavy atom derivative” refers to derivatives of S8 produced bychemically modifying a crystal of S8. In practice, a native crystal istreated by immersing it in a solution containing the desired metal salt,or organometallic compound, e.g., lead chloride, gold thiomalate,thimerosal or uranyl acetate, which upon diffusion into the proteincrystal can bind to the protein. The location of the bound heavy metalatom site(s) can be determined by X-ray diffraction analysis of thetreated crystal. This information, in turn, is used to generate thephase angle information needed to construct a three-dimensional electrondensity map from that a model of the atomic structure of the enzyme isderived (T. L. Blundel and N. L. Johnson, Protein Crystallography,Academic Press (1976)).

The term “space group” refers to the arrangement of entities (i.e.molecules) throughout the crystal lattice. There are only 132 possiblearrangements, each one unique and identified by a symbol. The spacegroup symbol is formed by a letter (P, F, I, C) and numbers with orwithout subscripts, for example: P2₁, I222, C2₁2₁2₁, etc.

Methods of Identifying Inhibitors of the S8 From Staphylococcus aureusCrystalline Structure

Another aspect of this invention involves a method for identifyinginhibitors of S8 protein characterized by the crystal structuredescribed herein, and the inhibitors themselves. The S8 crystalstructure of the invention permits the identification of inhibitors ofthe rRNA-binding activity of a Staphylococcus aureus S8. Such inhibitorsmay bind to all or a portion of the active site of the S8; or even becompetitive, non-competitive, or uncompetitive inhibitors. Onceidentified and screened for biological activity, these inhibitors may beused therapeutically or prophylactically to block the rRNA-bindingactivity of a Staphylococcus aureus S8, and thus, inhibit properassembly of the small ribosomal subunit.

One design approach is to probe the S8 crystal of the invention withmolecules composed of a variety of different chemical entities todetermine optimal sites for interaction between candidate inhibitors andthe rRNA-binding activity of S8. For example, high resolution X-raydiffraction data collected from crystals soaked in or co-crystallizedwith other molecules allows the determination of where each type ofsolvent molecule sticks. (J. Travis (1993) Science, 262:1374). Moleculesthat bind tightly to those sites can then be further modified andsynthesized and tested for the ability to inhibit rRNA-binding activityof S8.

The time-dependent analysis of structural changes in S8 protein duringits interaction with other molecules is permitted. The reactionintermediates of S8 protein can also be deduced from the reactionproduct in co-complex with S8 protein. Such information is useful todesign improved analogues of S8 protein inhibitors or to design classesof inhibitors based on the reaction intermediates of the S8 protein andbinding activity of S8 inhibitor co-complex. This provides a novel routefor designing S8 inhibitors with both high specificity and stability.

Another approach made possible by this invention, is to screencomputationally small molecule data bases for chemical entities orcompounds that can bind in whole, or in part, to the S8 protein. In thisscreening, the quality of fit of such entities or compounds to thebinding site may be judged either by shape complementarity or byestimated interaction energy (E. C. Meng et al, J. Comp. Chem.,13:505-524 (1992)).

Because S8 may crystallize in more than one crystal form, the structurecoordinates of S8, or portions thereof, as provided by this inventionare particularly useful to solve the structure of those other crystalforms of S8. They may also be used to solve the structure of S8 mutants,S8 co-complexes, or of the crystalline form of any other protein withsignificant amino acid sequence homology to any functional domain of S8.

One method that may be employed for this purpose is molecularreplacement. In this method, the unknown crystal structure, whether itis another crystal form of S8, an S8 mutant, or an S8 co-complex, or thecrystal of some other protein with significant amino acid sequencehomology to any functional domain of S8, may be determined using the S8structure coordinates of this invention as provided in Table 2. Thismethod will provide an accurate structural form for the unknown crystalmore quickly and efficiently than attempting to determine suchinformation ab initio.

Thus, the S8 structure provided herein permits the screening ofmolecules and/or the designing of new molecules that bind to the S8protein structure, particularly at the active site, via the use ofcomputerized evaluation systems. For example, computer modelling systemsare available in that the sequence of the S8, and the S8 structure(i.e., atomic coordinates of S8 and/or the atomic coordinate of theactive site cavity, bond angles, dihedral angles, distances betweenatoms in the active site region, etc. as provided by Table 2 herein) maybe input. Thus, a machine readable medium may be encoded with datarepresenting the coordinates of Table 2. The computer then generatesstructural details of the site into that a test compound should bind,thereby enabling the determination of the complementary structuraldetails of said test compound.

More particularly, the design of compounds that bind to or inhibit S8according to this invention generally involves consideration of twofactors. First, the compound must be capable of physically andstructurally associating with the S8 protein. Non-covalent molecularinteractions important in the association of S8 protein with its ligandsinclude hydrogen bonding, van der Waals and hydrophobic interactions.

Second, the compound must be able to assume a conformation that allowsit to associate with S8 protein. Although certain portions of thecompound will not directly participate in this association of an S8protein, those portions may still influence the overall conformation ofthe molecule. This, in turn, may have a significant impact on potency.Such conformational requirements include the overall three-dimensionalstructure and orientation of the chemical entity or compound in relationto all or a portion of the binding site, e.g., active site or accessorybinding site of S8 protein, or the spacing between functional groups ofa compound comprising several chemical entities that directly interactwith S8, such as rRNA.

The potential inhibitory or binding effect of a chemical compound on S8may be analyzed prior to its actual synthesis and testing by the use ofcomputer modelling techniques. If the theoretical structure of the givencompound suggests insufficient interaction and association between itand S8, synthesis and testing of the compound is obviated. However, ifcomputer modelling indicates a strong interaction, the molecule may thenbe synthesized and tested for its ability to bind to S8 and inhibitusing a suitable assay. In this manner, synthesis of inoperativecompounds may be avoided.

An inhibitory or other binding compound of S8 may be computationallyevaluated and designed by means of a series of steps in that chemicalentities or fragments are screened and selected for their ability toassociate with the individual binding pockets or other areas of S8protein.

One skilled in the art may use one of several methods to screen chemicalentities or fragments for their ability to associate with S8 and moreparticularly with the individual binding pockets of the S8 active siteor accessory binding site. This process may begin by visual inspectionof, for example, the active site on the computer screen based on the S8coordinates in Table 2. Selected fragments or chemical entities may thenbe positioned in a variety of orientations, or docked, within a bindingpocket of S8. Docking may be accomplished using software such as Quantaand Sybyl, followed by energy minimization and molecular dynamics withstandard molecular mechanics forcefields, such as CHARMM and AMBER.

Specialized computer programs may also assist in the process ofselecting fragments or chemical entities. These include:

-   -   1. GRID (P. J. Goodford, “A Computational Procedure for        Determining Energetically Favorable Binding Sites on        Biologically Important Macromolecules”, J. Med. Chem.,        28:849-857 (1985)). GRID is available from Oxford University,        Oxford, UK.    -   2. MCSS (A. Miranker and M. Karplus, “Functionality Maps of        Binding Sites: A Multiple Copy Simultaneous Search Method”,        Proteins: Structure, Function and Genetics, 11:29-34 (1991)).        MCSS is available from Molecular Simulations, Burlington, Mass.    -   3. AUTODOCK (D. S. Goodsell and A. J. Olsen, “Automated Docking        of Substrates to Proteins by Simulated Annealing”, Proteins:        Structure, Function, and Genetics, 8:195-202 (1990)). AUTODOCK        is available from Scripps Research Institute, La Jolla, Calif.    -   4. DOCK (I. D. Kuntz et al., “A Geometric Approach to        Macromolecule-Ligand Interactions”, J. Mol. Biol., 161:269-288        (1982)). DOCK is available from University of California, San        Francisco, Calif.

Additional commercially available computer databases for small molecularcompounds includes Cambridge Structural Database, Fine ChemicalDatabase, and CONCORD, for a review see Rusinko, A., Chem. Des. Auto.News 8, 44-47 (1993).

Once suitable chemical entities or fragments have been selected, theycan be assembled into a single compound or inhibitor. Assembly may beproceed by visual inspection of the relationship of the fragments toeach other on the three-dimensional image displayed on a computer screenin relation to the structure coordinates of S8 protein. This would befollowed by manual model building using software such as Quanta orSybyl.

Useful programs to aid one of skill in the art in connecting theindividual chemical entities or fragments include:

-   -   1. CAVEAT (P. A. Bartlett et al, “CAVEAT: A Program to        Facilitate the Structure-Derived Design of Biologically Active        Molecules”, in Molecular Recognition in Chemical and Biological        Problems”, Speical Pub., Royal Chem. Soc. 78, pp. 182-196        (1989)]. CAVEAT is available from the University of California,        Berkeley, Calif.    -   2. 3D Database systems such as MACCS-3D (MDL Information        Systems, San Leandro, Calif.). This area is reviewed in Y. C.        Martin, “3D Database Searching in Drug Design,” J. Med. Chem.,        35:2145-2154 (1992).    -   3. HOOK (available from Molecular Simulations, Burlington,        Mass.).

Instead of proceeding to build an S8 protein inhibitor in a step-wisefashion one fragment or chemical entity at a time as described above,inhibitory or other S8 binding compounds may be designed as a whole or“de novo” using either an empty active site or optionally including someportion(s) of a known ligand(s). These methods include:

-   -   1. LUDI (H. J. Bohm, “The Computer Program LUDI: A New Method        for the De Novo Design of Enzyme Inhibitors”, J. Comp. Aid.        Molec. Design, 6:61-78 (1992)). LUDI is available from Biosym        Technologies, San Diego, Calif.    -   2. LEGEND (Y. Nishibata and A. Itai, Tetrahedron, 47:8985        (1991)). LEGEND is available from Molecular Simulations,        Burlington, Mass.    -   3. LeapFrog (available from Tripos Associates, St. Louis, Mo.).

Other molecular modelling techniques may also be employed in accordancewith this invention. See, e.g., N. C. Cohen et al, “Molecular ModelingSoftware and Methods for Medicinal Chemistry”, J. Med. Chem., 33:883-894(1990). See also, M. A. Navia and M. A. Murcko, “The Use of StructuralInformation in Drug Design”, Current Opinions in Structural Biology,2:202-210 (1992). For example, where the structures of test compoundsare known, a model of the test compound may be superimposed over themodel of the structure of the invention. Numerous methods and techniquesare known in the art for performing this step, any of which may be used.See, e.g., P. S. Farmer, Drug Design, Ariens, E. J., ed., Vol. 10, pp119-143 (Academic Press, New York, 1980); U.S. Pat. No. 5,331,573; U.S.Pat. No. 5,500,807; C. Verlinde, Structure, 2:577-587 (1994); and I. D.Kuntz, Science, 257:1078-1082 (1992). The model building techniques andcomputer evaluation systems described herein are not a limitation on thepresent invention.

Thus, using these computer evaluation systems, a large number ofcompounds may be quickly and easily examined and expensive and lengthybiochemical testing avoided. Moreover, the need for actual synthesis ofmany compounds is effectively eliminated.

In another aspect, the S8 structure of the invention permit the designand identification of synthetic compounds and/or other molecules thathave a shape complimentary to the conformation of the S8 active site ofthe invention. Using known computer systems, the coordinates of the S8structure of the invention may be provided in machine readable form, thetest compounds designed and/or screened and their conformationssuperimposed on the structure of the invention. Subsequently, suitablecandidates identified as above may be screened for the desired S8inhibitory bioactivity, stability, and the like.

Once identified and screened for biological activity, these inhibitorsmay be used therapeutically or prophylactically to block rRNA-bindingactivity of S8, and thus, inhibit proper assembly of the small ribosomalsubunit.

As used herein the term “natural product molecule” includes allnon-synthetic products of nature and includes, but is not limited to,derivatives, extracts or homologs thereof, having, or containing, abioactive component.

Another aspect of this invention involves a method for identifyinginhibitors of a S8 characterized by the crystal structure andrRNA-binding site described herein. The S8 from S. aureus crystallinestructure of the invention permits the identification of inhibitors ofribosomal function. Such inhibitors may be competitive, binding to allor a portion of the rRNA-binding site of the S8; or non-competitive andbind to and inhibit ribosomal assembly or function whether or not it isbound to another chemical entity.

One design approach is to probe the S8 crystal of the invention withmolecules composed of a variety of different chemical entities todetermine optimal sites for interaction between candidate S8 inhibitorsand the protein. For example, high resolution X-ray diffraction datacollected from crystals saturated with solvent allows the determinationof where each type of solvent molecule binds. Small molecules that bindtightly to those sites can then be designed and synthesized and testedfor their S8 inhibitor activity.

This invention also enables the development of compounds that canisomerize to short-lived reaction intermediates in the chemical reactionof a substrate or other compound that binds to or with the S8. Thus, thetime-dependent analysis of structural changes in the S8 during itsinteraction with other molecules is permitted. The reactionintermediates of the S8 can also be deduced from the reaction product inco-complex with the S8. Such information is useful to design improvedanalogues of known S8 inhibitors or to design classes of inhibitorsbased on the reaction intermediates of the S8-rRNA and S8 inhibitorco-complex. This provides a route for designing S8 inhibitors with bothhigh specificity and stability.

Another approach made possible by this invention is to screencomputationally small molecule databases for chemical entities orcompounds that can bind in whole, or in part, to the S8 protein. Detailson this process and the results it can provide are now documented in theart. For a description of this type of technology please refer to PCTapplication WO 97/16177 published May 9, 1997; the techniques describedthere for computer modeling are incorporated herein by reference.

Once identified by the modeling techniques, the inhibitor of ribosomalfunction may be tested for bio-activity using standard techniques. Forexample, the structure of the invention may be used in activity assaysto determine the inhibitory activity of the compounds or binding assaysusing conventional formats to screen inhibitors. One particularlysuitable assay format includes the enzyme-linked immunosorbent assay(ELISA). Other assay formats may be used; these assay formats are not alimitation on the present invention.

In another aspect, the S8 structure of the invention permit the designand identification of synthetic compounds and/or other molecules thatare characterized by the conformation of the S8 of the invention. Usingknown computer systems, the coordinates of the S8 structure of theinvention may be provided in machine readable form, the test compoundsdesigned and/or screened and their conformations superimposed on thestructure of the S8 of the invention. Subsequently, suitable candidatesidentified as above may be screened for the desired inhibitorybio-activity, stability, and the like.

Once identified and screened for biological activity, these inhibitorsmay be used therapeutically or prophylactically to block S8 function,and thus, overcome bacterial resistance to antibiotics, for example, ofthe beta-lactam class, eg. imipenem, penicillins, cephalosporins, etc.by using an entirely different mechanism of attacking bacteria indiseases produced by bacterial infection.

The following examples illustrate various aspects of this invention.These examples do not limit the scope of this invention that is definedby the appended claims.

EXAMPLE 1 The Expression and Purification of the S8 From Staphylococcusaureus in Escherichia coli

The gene for S. aureus S8 was PCR amplified from strain WCUH29 genomicDNA, and the resulting fragment was cloned into pET28a(+) for expressionin E. coli. The S. aureus S8-expression construct (S8sa-pET28) wastransformed into BL21(DE3) cells for expression and purified by cationexchange chromatography. The soluble polypeptide includes 132 amino acidresidues with a molecular weight of 14,830 Da. This product was greaterthan 95% pure by SDS PAGE, has the desired RNA-binding activity, andN-terminal amino acid analysis confirmed its identity. A one literculture of E. coli haboring the S8 expression construct was induced withIPTG for three hours at 37° C. FIG. 2 shows that very little of theoverexpressed protein was present in the soluble fraction (lane 5).After solubilization of the protein in 6M urea and purification by anionexchange chromatography, the resulting protein appeared to be greaterthan 95% pure. N-terminal sequencing, MALDI-MS and AA analysis allconfirmed the identity of the purified protein.

1.A. Measurement of S8 Activity.

It is also possible to define ligand interactions with S8 in experimentsthat are not dependent upon enzyme catalyzed turnover of substrates.This type of experiment can be done in a number of ways:

1.B. 1. Effects of Ligand Binding Upon Intrinsic Fluorescence (e.g. ofTryptophan).

Binding of either natural ligands or inhibitors may result in theprotein's conformational changes that alter its fluorescence. Usingstopped-flow fluorescence equipment, this can be used to define themicroscopic rate constants that describe binding. Alternatively,steady-state fluorescence titration methods can yield the overalldissociation constant for binding in the same way that these areaccessed through enzyme inhibition experiments.

EXAMPLE 2 Crystallization, Structure Determination and Refinement of theCrystal Structure of the S8 From S. aureus

2.A. Crystallization

Single crystals of native S8 grew from sitting drops prepared by mixing2 μL protein with 2 μL of reservoir solution containing 30% PEG4000,0.2M Li₂SO₄, 0.1M Tis-HCl, pH 8.5. The drops were left to equilibrate atroom temperature against 500μL of the reservoir solution. By registeringthe position and intensity of many tens of thousands of diffractionspots using the computer program HKL2000 (Otwinowski, Z. and Minor, W.(1996) Methods in Enzymology 276, 307-326) and, program MOSFLM (A. G. W.Leslie, MRC Laboratory of Molecular Biology, Hills Road, Cambridge, UKand Collaborative Computational Project, Number 4, (1994) Acta Cryst.D50, 760-763.) the crystal has been determined to be the orthorhombicspace group P2₁2₁2₁ and have unit cell parameters (lattice constants):a=42.1 Å, b=55.9 Å, c=61.3 Å, alpha=beta=gamma=90.0° and one molecule inthe asymmetric unit.

2.B. X-Ray Diffraction Data Collection

The crystal was picked up with a loop and frozen by quickly submergingit into liquid nitrogen before mounting it under the cold stream.Diffraction data was collected at CHESS F2 beamline using 1.000 Åwavelength x-rays and the ADSC QuantumIV detector. The data wasintegrated, reduced and scaled with DPS/MOSFLMWSCALA (CCP4). The datacollection statistics are shown in Table 3.

2.C. Structure Determination

The structure was determined by molecular replacement using the programAmoRe (Navaza). and the atomic coordinates of the S8 structure from B.stearothermophylus (ISEI). The solution had a correlation coefficient of0.50 and R=0.49. The correct amino acid sequence was traced beforerefinement. The suite of programs CNX was used for the refinement andthe interactive graphics program O was used for manipulating the model.The final model includes residue 4 to 132 and 281 water molecules.Residues 1 to 3 are not visible in the electron density map.

2.D. Model Building and Refinement

The electron density map was of high quality and afforded the placementof the complete molecule using the interactive computer graphics programO (Jones, T. A. et al. (1991) Acta Crystallogr. A47: 110-119). The modelwas refined against diffraction data by successive rounds of simulatedannealing with torsion angle dynamics, positional refinement andrestrained B-factor refinement using CNX (A. Brunger et al., Science,235: 458-460 (1987)) followed by manual intervention. The refinement andmanual rebuilding was monitored by the quality of the 2Fo-Fc and Fo-Fcelectron density maps and the value of the crystallographic R andR_(free). The final R is 0.19 and the R_(free) is 0.23 for 23,473reflections to 1.50 Å resolution. The rms deviation from the referencebond lengths and bond angles (Engh & Huber (1991) Acta Crystallogr. A47:392-400) are 0.017 Å and 1.8°, respectively. The refined model includesresidues 4-132 according to the amino acid sequence SEQ ID NO:1. TheN-terminal residues 1 to 3 were disordered in the four molecules. In therefined model, all the main chain conformations fall in the “allowed”regions of the Ramachandran plot. The refinement statistics are shown inTable 4.

EXAMPLE 3 Identifying Inhibitors of Activity of the S. aureus S8 Protein

Avi-tagged S8 was expressed in E. coli along with with BirA (biotinligase), and LC/MS indicated that approximately 50% of the S8 containedthe biotin group at the N-terminus (data not shown). RNA filter-bindingstudies established that the biotinylated Avi-tagged S8 proteinrecognized Helix 21 rRNA with an affinity comparable to the untaggedprotein, Table 5, indicating that the peptide tag and subsequentlabeling have no adverse effect on RNA-protein recognition. Thisbiotinylated protein was then used to develop a highthroughput-screening assay, which will be used to detect inhibitors ofthe S8-rRNA interaction. The basis of the scintillation proximity assayis shown in FIG. 5. Essentially, the Helix 21 rRNA fragment is labeledwith ³³P or ³H (either internally or at the -3′ or 5′-ends), and acomplex is allowed to form with the biotinylated S8 protein. Afterformation of the RNA-protein complex, streptavidin SPA beads (AmershamPharmacia) are added and incubated with the RNA-protein complex, and thesamples are read in a microplate scintillation counter (eg, TopCount byPackard). Using biotinylated (Avi-tagged) S. aureus ribosomal proteinS8, ³³P-labeled helix 21 RNA, and streptavidin SPA beads, a specificsignal due to protein-RNA binding was detected, FIG. 6(a). When Helix 21ΔA649 substrate was used in the SPA assay, no signal above backgroundcould be detected, indicating the validity of the SPA format as a viableassay to examine S8-rRNA interactions, FIG. 6(b). The specificity ofS8-rRNA recognition was further validated in the SPA format by titratingthe binding reactions with unlabeled cognate and non-cognate RNAs.Results show that the addition of excess, unlabeled, wild-type Helix 21RNA competes the SPA signal to near background levels, while theaddition of like amounts of Helix 21 ΔA649 RNA does not (data notshown). This further indicates that the SPA format reflects truerecognition of 16S rRNA by S8 protein. This assay can be transferred toa multi-well format (example, 96- or 384-well microplates) for highthroughput screening of diverse compound collections. Such compoundsthat inhibit the S8-rRNA interaction may be useful anti-bacterials.

3.A. Cloning of S. aureus S8

The gene for S. aureus S8 was PCR amplified from strain WCUH29 genomicDNA using a forward primer containing a BspHI site (5′-ACTTCCTCATGACAATGACAGATCCAATCG-3) and a reverse primer containing a HindIIIsite (5′-CTTCTCAAGCTTTTACCAAACGTATGCGATAA-3). The 419 bp fragment wasdigested with BspHI and HindIII, purified, and ligated into pET28a(+)cut with NcoI and HindIII. Positive transformants were confirmed bysequencing.

3.B. pET24-AviTag Vector Construction

A linker was made encoding the AviTag (Avidity, see below) with an NdeI5′ overhang, 3′ BamHI overhang and containing a unique ScaI site afterthe tag. This was ligated into pET24b(+) from Novagen cut with NdeI andBamHI. 5′T ATG GCT GGT GGC CTG AAC GAT ATT TTC GAA GCT CAG 3′   AC CGACCA CCG GAC TTG CTA TAA AAG CTT CGA GTC     M   A   G   G   L   N   D   I   F   E   A   Q AAA ATC GAA TGG CATGAA AGT ACT G   3′ TTT TAG CTT ACC GTA CTT TCA TGA C CTA G 5′   K  I   E   W   H   E   S3.C. Cloning of AviTag-S8 Construct

The intact S. aureus S8 gene was PCR amplified from WCUH29 genomic DNAusing Pwo polymerase (Roche) and the following primers: forward(5′-ATGACAATGACAGATCCAATCGC-3′) and reverse(5′-TTTACCAAACGTATGCGATAATTTC-3′). The 400 bp fragment was kinased andligated into pET24-AviTag digested with ScaI and dephosphorylated. Theconstruct was confirmed by sequencing and transformed into BL21(DE3)cells containing pACYCbirA (Avidity) for expression of thebiotinylated-AviTag-S8.

3.D. Protein Expression and Purification

The S. aureus S8-expression construct (S8sa-pET28) was transformed intoBL21(DE3) cells for expression and a 10 ml overnight culture in LB, 50ug/ml Kanamycin, 1% glucose was diluted 1:100 and grown to an OD₆₀₀ of0.55. IPTG was added to 0.5 mM and induction carried out for 3 h at 37°C. Cells were lysed in 30ml (5 ml/g wet weight) of 50 mM Na-phosphate pH7.5 and lysed via sonication and freeze/thaw. After centrifugation, thepellet was solubilized in 30 ml of 6M Urea/20 mM Tris pH 7.0 (BufferA)and the filtered supernatant applied to a 5 ml HiTrap SP column. S8was eluted with a 40 column volume gradient of 0-1M NaCl in Buffer A.Fractions containing S8 were pooled and refolded by dialysis againstseveral changes of 80 mM Hepes pH 7.6 and 1M KCl. Aliquots were frozenin a dry ice/ethanol bath and stored at −80° C. Integrity of the proteinwas confirmed by N-terminal sequencing, MALDI-MS and AA analysis. Yieldfrom the 1 liter culture was 36 mg of purified protein.

3.E. Expression and Purification of B-Avi-S8

5 ml of an overnight LB/Kanamycin (50 ug/ml)/Chloramphenicol (34ug/ml)/1% glucose culture was diluted 100-fold into media containing 50uM biotin. The culture was grown at 37° C./250 rpm to an OD₆₀₀ of 0.5,IPTG was added to 0.5 mM and growth continued at 37° C. for anadditional 3 h. Pelleted cells were homogenized in 6M Urea/20 mM TrispH7.0 (BufferA) in a volume of 5 ml/g cells. Clarified lysate wasapplied to a 5 ml HiTrapSP column (Amersham Pharmacia) and eluted with a40 column volume gradient of 0-1M NaCl in BufferA. Fractions containingB-Avi-S8 were pooled and dialized at 4° C. against 80 mM Hepes pH 7.6/1MKCl. Aliquots were quick-frozen and stored at −80° C. N-terminalsequencing, LC/MS and AA analysis confirm the integrity of the protein.Yield was 14 mg of greater than 90% purity from a 500 ml culture with−50% biotinylation.

3.F. Cloning and Transcription of Helix 21 rRNAs

A DNA fragment corresponding to Helix 21 (nts 584-655) of E. coli 16SrRNA was amplified by PCR of E. coli genomic DNA. A T7-promoter sequencewas incorporated into the fragment by the 5′-primer, and the fragmentwas cloned into the EcoRI-Kpnl sites of pUC19 to generate pUC-EcH21.Helix 21 from Staphylococcus aureus (corresponding to nts 596-659 of 16SrRNA) was cloned downstream of a T7 promoter in a similar manner togenerate the plasmid pUC-SaH21. The generation of mutant derivatives ofS. aureus Helix 21 was done by incorporation of site directedmutagenesis of PCR primers. Unlabeled RNAs were trancribed fromBamHI-linearized DNA templates using MEGAshortscript kit (Ambion Inc.,Austin, Tex.). RNA substrates for filter-binding studies were made byend-labeling with γ-³²P or ³³P-ATP.

3.G. Filter-Binding

For filter-binding experiments, labeled RNAs were renatured bypreincubation in binding buffer (80 mM HEPES-KOH pH 7.6, 350 mM KOAc, 20mM MgOAc) for fifteen minutes at 40° C. Renatured RNA was then mixedwith the appropriate amount of protein and then incubated for fifteenminutes on ice and then filtered immediately on 0.45 μM nitrocellulosefilters (Whatman), washed with 1.0 ml of binding buffer, and thencounted in a scintillation counter. K_(d)'s were determined from severalindependent binding experiments for each substrate RNA.

3.H. Characterisation of the RNA-Binding Activity of S. aureus S8

In order to characterise the RNA-binding activity of S. aureus S8, anRNA-filter-binding assay was developed. The results of theseexperiments, shown in FIG. 3, demonstrate that the interaction of S8with wild-type Helix 21 RNA has a measured affinity of approximately 400nM. This interaction is highly specific, in that an RNA containing adeletion of A603 fails to demonstrate any appreciable binding by S8.This result also highlights the importance of the base triple withinhelix 21, as A603 is predicted to interact with the A604-U652 basepair.

Several mutations were introduced into Helix 21 rRNA, shown in FIG. 4,and the apparent dissociation constants for the interaction of S8 andthese variant RNA substrates was examined. These results are shown inTable 5. Substitution of the A-U base pair (nts 604-652) with G-C resultin a tenfold decrease in binding affinity. This nucleotide substitutionis predicted to maintain the stem structure in this region but itchanges the primary sequence of the RNA. Since S8 still binds to thisRNA, albeit at a tenfold decreased affinity, this underscores the factthat while maintenance of the secondary structure in this region isrequired, the exact sequence of the RNA is necessary for optimalrecognition by S8. Deletion of A649, and substitutions of C651-U andA650C651-U all result in the complete abrogation of binding by S8,suggesting the critical importance of nucleotides in this region. Theconserved nature of this RNA-protein recognition is further demonstratedby the fact that S. aureus S8 can recognize E. coli Helix 21 rRNA with asimilar affinity as with S. aureus Helix 21 rRNA.

EXAMPLE 4 Modeling Studies of S. aureus S8-rRNA Binding

Superposition of the S. aureus S8 onto the S8 in the S30 ribosomalsubunit of T thermophilus (1FJG), shown in FIG. 12(a), indicates thatthere are two regions of interaction with the rRNA: residues 5-19(N-terminal α-helix) with nucleotides A820-A885 and residues 4-6, 30-32,56-57, 82-92, 107-111, and 122-125 with nucleotides A587-A758. Thissecond RNA-interacting face is in direct contact with bases and morelikely the surface to target with inhibitors that disrupt the S8-rRNAinteraction(s).

The surface representation of S. aureus S8 protein is shown in FIG.14(a). The N-terminus, colored light blue, is the region predicted tobind to rRNA in T. thermophylus S30 ribosomal particle and presumablyalso in S. aureus where it rides on the rRNA formed by a double strandedstem structure formed by nucleotides A587 to A758 in 1FJG. In FIG.14(b), the calculated surface electrostatic potential shows that theS8-rRNA interactions are not predominantly electrostatic. In thisinteracting surfaces there appears to be cavities between protein andthe rRNA that may accommodate drug(s) that could interfere with thenormal S8-rRNA interaction.

FIG. 13 shows a model of T. thermophilus helix 21 rRNA binding to the“underside” of S. aureus S8. S8 residues S107, T108, S109, and E126 makecontacts with helix 21 nts A642, C643, and G644 (the highly-conservedbase triple). This modeling data is consistent with the biochemical datashowing that nucleotides in this base triple are critical for accuraterecognition by S. aureus S8 as shown in Table 5. TABLE 1 E. H. P. M. S.B. S. S. E. coli influenzas aeruginosa catarrhalis aureus subtilispneumoniae pyogenes faecalis Human 100 84 62 58 48 47 47 45 47 23 E.coli 100 62 63 45 45 45 45 45 22 H. influenzae 100 56 43 46 45 42 45 24P. aeruginosa 100 46 46 45 46 47 23 M. catarrhalis 100 77 74 78 77 22 S.aureus 100 72 77 81 27 B. subtilis 100 91 80 29 S. pneumoniae 100 84 26S. pyogenes 100 27 E. faecalis 100 Human

TABLE 3 Data collection statistics Resolution, Å Complete, %Multiplicity I/σ<I> R_(sym) 4.74 95.8 2.7 14.6 0.040 3.35 99.3 3.0 17.20.035 2.74 99.8 3.1 14.6 0.037 2.37 99.9 3.2 11.9 0.051 2.12 99.9 3.29.1 0.068 1.94 100.0 3.2 8.3 0.077 1.79 100.0 3.2 5.8 0.115 1.68 100.03.2 4.3 0.155 1.58 99.7 3.1 3.1 0.213 1.50 97.5 2.7 2.5 0.274 99.4 3.18.4 0.053

TABLE 4 Refinement statistics Resolution 20-1.5Å No. Reflections 23,473Completeness 99.2% R 0.19 R_(free) 0.23 No. protein atoms 1049 No.solvent atoms 281 rms deviation from ideal: bond length 0.017Å bondangle 1.8°Table 2. Atomic Coordinates of the Native S8 StructureLegend:

1. Under the heading ATOM appears a “atom number” (e.g. 1,2,3,4 . . .etc) and the “atom name” (e.g. CA, CB, N, . . . etc) such that to each“atom name” in the coordinate list corresponds an “atom number”.

2. Under the heading RESIDUE appears a three-letter “residue name” (e.gTHR, ASP, etc), a “chain identifier” represented by a capital letter(e.g. A, B, C D, etc) and a “residue number”, such that to each residue(or amino acid) in the amino acid sequence of the particular protein inthe structure corresponds a name that identifies it, a number accordingto its position along the amino acid sequence, and a chain name. Thechain name identifies a particular molecule in the crystal structure.For instance, if there are more than one molecule that form the unitthat is repeated throughout the crystal lattice, then each unit isidentified as molecule A, or molecule B, or molecule C, etc

3. Under the headings X, Y, or Z appear the Cartesian coordinates of theatoms in the structure

4. Under the heading OCC appears the “occupancy factor” for each atom.If the entity is present and observed in the structure then an occupancyof 1.00 is assigned to it. If the atom is present but not observed, anoccupancy of 0.00 is assigned to it. Also, factors between 0.00 and 1.00are also acceptable and represent the degree of confidence in observingthat atom a that particular position.

5. Under the heading B appears the “B-factor” or “temperature factor”that can adopt, in principle, any value. It is meant to represent theatomic displacement around that position. Atomic coordinates of thenative S8 structure CRYST1 42.100 55.500 61.400 90.00 90.00 90.00 ATOMRESIDUE X Y Z Occ B 1 CB THR A 4 −6.461 24.691 −0.181 1.00 42.83 2 OG1THR A 4 −5.711 24.797 −1.400 1.00 45.08 3 CG2 THR A 4 −7.614 23.708−0.339 1.00 45.36 4 C THR A 4 −5.729 26.957 0.416 1.00 33.79 5 O THR A 4−5.382 27.840 −0.383 1.00 33.22 6 N THR A 4 −7.982 26.637 −0.747 1.0037.31 7 CA THR A 4 −6.977 26.097 0.220 1.00 39.29 8 N ASP A 5 −5.02526.661 1.495 1.00 23.47 9 CA ASP A 5 −3.817 27.419 1.821 1.00 17.33 10CB ASP A 5 −4.144 28.279 3.011 1.00 15.38 11 CG ASP A 5 −2.929 29.0063.517 1.00 14.79 12 OD1 ASP A 5 −1.887 28.833 2.888 1.00 15.80 13 OD2ASP A 5 −3.079 29.711 4.494 1.00 14.90 14 C ASP A 5 −2.759 26.362 2.1471.00 16.58 15 O ASP A 5 −2.704 25.870 3.281 1.00 18.05 16 N PRO A 6−1.903 26.000 1.177 1.00 16.44 17 CD PRO A 6 −1.858 26.464 −0.226 1.0020.90 18 CA PRO A 6 −0.887 24.971 1.423 1.00 17.38 19 CB PRO A 6 −0.11624.882 0.115 1.00 19.60 20 CG PRO A 6 −1.151 25.310 −0.906 1.00 24.25 21C PRO A 6 0.037 25.237 2.573 1.00 16.97 22 O PRO A 6 0.526 24.286 3.2141.00 14.81 23 N ILE A 7 0.313 26.514 2.830 1.00 13.93 24 CA ILE A 71.212 26.837 3.939 1.00 12.98 25 CB ILE A 7 1.682 28.282 3.865 1.0013.39 26 CG2 ILE A 7 2.495 28.601 5.156 1.00 13.95 27 CG1 ILE A 7 2.57428.470 2.624 1.00 16.70 28 CD1 ILE A 7 2.955 29.946 2.375 1.00 17.46 29C ILE A 7 0.489 26.529 5.247 1.00 14.00 30 O ILE A 7 1.106 25.894 6.1201.00 14.04 31 N ALA A 8 −0.761 26.953 5.427 1.00 14.80 32 CA ALA A 8−1.482 26.605 6.644 1.00 13.39 33 CB ALA A 8 −2.869 27.199 6.629 1.0013.83 34 C ALA A 8 −1.565 25.053 6.751 1.00 13.55 35 O ALA A 8 −1.44624.453 7.843 1.00 15.03 36 N ASP A 9 −1.791 24.363 5.635 1.00 15.10 37CA ASP A 9 −1.858 22.908 5.763 1.00 17.82 38 CB ASP A 9 −2.198 22.2624.410 1.00 18.75 39 CG ASP A 9 −3.558 22.657 3.887 1.00 21.83 40 OD1 ASPA 9 −4.455 23.107 4.646 1.00 25.74 41 OD2 ASP A 9 −3.736 22.501 2.6541.00 28.91 42 C ASP A 9 −0.533 22.332 6.276 1.00 14.90 43 O ASP A 9−0.542 21.378 7.067 1.00 16.11 44 N MET A 10 0.597 22.861 5.827 1.0013.05 45 CA MET A 10 1.906 22.383 6.285 1.00 14.46 46 CB MET A 10 3.07123.090 5.575 1.00 13.13 47 CG MET A 10 4.441 22.738 6.164 1.00 12.70 48SD MET A 10 5.626 23.707 5.172 1.00 15.11 49 CE MET A 10 7.153 23.0705.887 1.00 13.64 50 C MET A 10 2.043 22.644 7.773 1.00 12.35 51 O MET A10 2.446 21.742 8.503 1.00 13.00 52 N LEU A 11 1.741 23.853 8.222 1.0013.28 53 CA LEU A 11 1.883 24.174 9.640 1.00 11.41 54 CB LEU A 11 1.44425.617 9.913 1.00 10.89 55 CG LEU A 11 2.303 26.671 9.158 1.00 11.59 56CD1 LEU A 11 1.757 28.056 9.614 1.00 12.36 57 CD2 LEU A 11 3.809 26.5629.385 1.00 14.75 58 C LEU A 11 1.029 23.226 10.476 1.00 13.64 59 O LEU A11 1.471 22.766 11.515 1.00 13.28 60 N THR A 12 −0.192 22.948 10.0241.00 11.82 61 CA THR A 12 −1.082 22.038 10.735 1.00 12.04 62 CB THR A 12−2.473 22.064 10.085 1.00 13.84 63 OG1 THR A 12 −3.033 23.348 10.3331.00 15.75 64 CG2 THR A 12 −3.388 21.020 10.697 1.00 19.14 65 C THR A 12−0.548 20.628 10.749 1.00 13.77 66 O THR A 12 −0.651 19.923 11.768 1.0014.02 67 N ARG A 13 −0.018 20.151 9.633 1.00 14.34 68 CA ARG A 13 0.56918.795 9.623 1.00 15.56 69 CB ARG A 13 1.106 18.446 8.216 1.00 17.77 70CG ARG A 13 0.003 18.123 7.182 1.00 20.88 71 CD ARG A 13 −0.743 16.8277.511 1.00 25.58 72 NE ARG A 13 0.198 15.737 7.751 0.75 27.19 73 CZ ARGA 13 1.008 15.198 6.833 1.00 29.03 74 NH1 ARG A 13 1.006 15.633 5.5801.00 33.07 75 NH2 ARG A 13 1.846 14.232 7.186 1.00 31.78 76 C ARG A 131.708 18.724 10.658 1.00 13.44 77 O ARG A 13 1.784 17.737 11.426 1.0014.13 78 N VAL A 14 2.564 19.762 10.721 1.00 12.16 79 CA VAL A 14 3.68319.767 11.669 1.00 14.68 80 CB VAL A 14 4.629 20.954 11.397 1.00 11.8581 CG1 VAL A 14 5.649 21.137 12.586 1.00 12.44 82 CG2 VAL A 14 5.38020.736 10.084 1.00 12.20 83 C VAL A 14 3.120 19.855 13.087 1.00 11.52 84O VAL A 14 3.578 19.108 13.967 1.00 12.95 85 N ARG A 15 2.098 20.67213.301 1.00 11.56 86 CA ARG A 15 1.503 20.856 14.621 1.00 10.79 87 CBARG A 15 0.346 21.843 14.578 1.00 11.82 88 CG ARG A 15 −0.211 22.23215.946 1.00 11.89 89 CD ARG A 15 −1.464 23.174 15.884 1.00 13.82 90 NEARG A 15 −1.098 24.376 15.121 1.00 14.40 91 CZ ARG A 15 −1.509 24.66013.888 1.00 16.35 92 NH1 ARG A 15 −2.346 23.837 13.259 1.00 15.77 93 NH2ARG A 15 −1.028 25.719 13.210 1.00 14.51 94 C ARG A 15 0.958 19.52915.132 1.00 10.68 95 O ARG A 15 1.215 19.125 16.273 1.00 13.61 96 N ASNA 16 0.240 18.827 14.253 1.00 12.18 97 CA ASN A 16 −0.346 17.556 14.6611.00 15.25 98 CB ASN A 16 −1.341 17.080 13.590 1.00 16.21 99 CG A ASN A16 −2.549 18.008 13.398 0.50 18.74 100 CG B ASN A 16 −1.824 15.67613.859 0.50 20.66 101 OD1A ASN A 16 −3.286 17.894 12.397 0.50 20.74 102OD1B ASN A 16 −1.176 14.706 13.455 0.50 21.76 103 ND2A ASN A 16 −2.77218.898 14.336 0.50 18.12 104 ND2B ASN A 16 −2.953 15.556 14.570 0.5018.81 105 C ASN A 16 0.711 16.475 14.903 1.00 13.65 106 O ASN A 16 0.61915.702 15.912 1.00 15.21 107 N ALA A 17 1.728 16.355 14.032 1.00 13.10108 CA ALA A 17 2.773 15.354 14.192 1.00 14.08 109 CB ALA A 17 3.75815.372 12.963 1.00 13.25 110 C ALA A 17 3.571 15.588 15.463 1.00 12.71111 O ALA A 17 3.954 14.630 16.129 1.00 12.71 112 N ASN A 18 3.80916.866 15.795 1.00 11.25 113 CA ASN A 18 4.544 17.266 16.992 1.00 12.37114 CB ASN A 18 4.745 18.804 16.933 1.00 12.25 115 CG ASN A 18 5.59519.334 18.082 1.00 11.43 116 OD1 ASN A 18 6.644 18.759 18.401 1.00 13.81117 ND2 ASN A 18 5.148 20.396 18.705 1.00 13.40 118 C ASN A 18 3.72616.858 18.230 1.00 10.83 119 O ASN A 18 4.291 16.311 19.197 1.00 11.44120 N MET A 19 2.421 17.120 18.179 1.00 12.24 121 CA MET A 19 1.55316.767 19.300 1.00 12.44 122 CB MET A 19 0.111 17.135 18.992 1.00 12.44123 CG MET A 19 −0.835 16.721 20.145 1.00 13.33 124 SD MET A 19 −2.53617.145 19.741 1.00 18.49 125 CE MET A 19 −2.867 15.921 18.627 1.00 20.10126 C MET A 19 1.632 15.281 19.608 1.00 13.50 127 O MET A 19 1.74014.873 20.782 1.00 13.60 128 N VAL A 20 1.538 14.452 18.562 1.00 12.37129 CA VAL A 20 1.579 12.989 18.807 1.00 13.21 130 CB VAL A 20 0.65612.247 17.810 1.00 15.22 131 CG1 VAL A 20 −0.730 12.812 17.910 1.0014.43 132 CG2 VAL A 20 1.255 12.328 16.378 1.00 16.73 133 C VAL A 202.977 12.382 18.868 1.00 16.11 134 O VAL A 20 3.177 11.144 18.847 1.0019.83 135 N ARG A 21 3.989 13.256 18.917 1.00 13.57 136 CA ARG A 215.382 12.881 19.060 1.00 14.55 137 CB ARG A 21 5.621 12.188 20.422 1.0014.10 138 CG ARG A 21 5.330 13.146 21.572 1.00 10.31 139 CD A ARG A 215.546 12.449 22.926 0.50 9.37 140 CD B ARG A 21 5.543 12.473 22.941 0.5013.63 141 NE A ARG A 21 5.322 13.318 24.071 0.50 5.45 142 NE B ARG A 215.749 13.534 23.896 0.50 20.38 143 CZ A ARG A 21 6.249 14.148 24.5410.50 7.97 144 CZ B ARG A 21 6.905 14.178 24.000 0.50 17.62 145 NH1A ARGA 21 7.438 14.232 23.955 0.50 11.73 146 NH1B ARG A 21 7.938 13.83923.243 0.50 16.00 147 NH2A ARG A 21 6.001 14.869 25.591 0.50 13.99 148NH2B ARG A 21 6.999 15.205 24.787 0.50 9.14 149 C ARG A 21 5.929 11.98517.950 1.00 19.18 150 O ARG A 21 6.742 11.110 18.212 1.00 19.79 151 NHIS A 22 5.490 12.236 16.714 1.00 17.02 152 CA HIS A 22 6.034 11.46815.596 1.00 18.66 153 CB HIS A 22 5.294 11.744 14.280 1.00 19.15 154 CGHIS A 22 3.964 11.071 14.152 1.00 20.64 155 CD2 HIS A 22 2.849 11.43613.473 1.00 24.91 156 ND1 HIS A 22 3.648 9.905 14.816 1.00 30.45 157 CE1HIS A 22 2.394 9.585 14.559 1.00 29.06 158 NE2 HIS A 22 1.884 10.49813.749 1.00 33.58 159 C HIS A 22 7.508 11.849 15.369 1.00 19.73 160 OHIS A 22 7.941 13.005 15.558 1.00 17.77 161 N GLU A 23 8.270 10.88814.855 1.00 19.88 162 CA GLU A 23 9.664 11.113 14.541 1.00 20.11 163 CBGLU A 23 10.358 9.768 14.260 1.00 27.37 164 CG GLU A 23 11.815 9.90513.819 1.00 30.59 165 CD GLU A 23 12.429 8.591 13.293 1.00 40.76 166 OE1GLU A 23 11.709 7.766 12.678 1.00 43.53 167 OE2 GLU A 23 13.651 8.40813.481 1.00 47.87 168 C GLU A 23 9.729 11.975 13.274 1.00 16.44 169 OGLU A 23 10.616 12.791 13.138 1.00 16.55 170 N LYS A 24 8.774 11.76012.380 1.00 16.86 171 CA LYS A 24 8.785 12.509 11.109 1.00 19.29 172 CBLYS A 24 9.759 11.818 10.132 1.00 21.65 173 CG LYS A 24 9.201 10.5339.541 1.00 28.20 174 CD LYS A 24 10.257 9.774 8.783 1.00 31.38 175 CELYS A 24 11.155 9.031 9.726 0.50 33.74 176 NZ LYS A 24 11.650 9.92610.809 0.50 33.81 177 C LYS A 24 7.408 12.562 10.493 1.00 17.40 178 OLYS A 24 6.445 11.905 10.940 1.00 18.36 179 N LEU A 25 7.305 13.3569.425 1.00 16.29 180 CA LEU A 25 6.086 13.453 8.672 1.00 17.35 181 CBLEU A 25 5.117 14.499 9.247 1.00 17.32 182 CG LEU A 25 5.595 15.9549.132 1.00 16.73 183 CD1 LEU A 25 4.366 16.848 9.061 1.00 21.28 184 CD2LEU A 25 6.520 16.367 10.286 1.00 19.12 185 C LEU A 25 6.467 13.8057.228 1.00 16.64 186 O LEU A 25 7.582 14.278 6.964 1.00 16.92 187 N GLUA 26 5.557 13.491 6.322 1.00 18.27 188 CA GLU A 26 5.785 13.801 4.9031.00 18.14 189 CB GLU A 26 5.813 12.499 4.063 1.00 17.91 190 CG GLU A 267.116 11.762 4.199 1.00 24.85 191 CD GLU A 26 7.103 10.438 3.491 1.0029.39 192 OE1 GLU A 26 6.263 10.245 2.563 1.00 30.78 193 OE2 GLU A 267.946 9.602 3.879 1.00 35.10 194 C GLU A 26 4.660 14.652 4.429 1.0016.57 195 O GLU A 26 3.523 14.477 4.840 1.00 22.49 196 N LEU A 27 4.95615.625 3.564 1.00 16.18 197 CA LEU A 27 3.917 16.450 3.000 1.00 19.66198 CB LEU A 27 3.661 17.706 3.869 1.00 22.81 199 CG LEU A 27 4.88418.573 4.237 1.00 25.00 200 CD1 LEU A 27 4.664 19.914 3.610 1.00 22.75201 CD2 LEU A 27 5.029 18.750 5.734 1.00 28.32 202 C LEU A 27 4.32316.842 1.571 1.00 17.53 203 O LEU A 27 5.495 16.802 1.239 1.00 19.86 204N PRO A 28 3.349 17.237 0.736 1.00 20.65 205 CD PRO A 28 1.927 17.4911.004 1.00 20.94 206 CA PRO A 28 3.704 17.621 −0.645 1.00 20.41 207 CBPRO A 28 2.361 18.010 −1.258 1.00 23.88 208 CG PRO A 28 1.321 17.286−0.347 1.00 27.18 209 C PRO A 28 4.673 18.799 −0.653 1.00 20.38 210 OPRO A 28 4.556 19.748 0.129 1.00 19.44 211 N ALA A 29 5.603 18.790−1.593 1.00 18.16 212 CA ALA A 29 6.564 19.853 −1.704 1.00 21.72 213 CBALA A 29 7.848 19.311 −2.300 1.00 19.37 214 C ALA A 29 6.108 21.022−2.553 1.00 18.53 215 O ALA A 29 5.245 20.890 −3.436 1.00 18.27 216 NSER A 30 6.626 22.190 −2.201 1.00 18.34 217 CA SER A 30 6.449 23.411−3.047 1.00 16.19 218 CB SER A 30 5.183 24.209 −2.727 1.00 20.14 219 OGSER A 30 5.339 24.974 −1.529 1.00 21.32 220 C SER A 30 7.708 24.222−2.777 1.00 15.57 221 O SER A 30 8.472 23.997 −1.798 1.00 18.05 222 NASN A 31 7.994 25.191 −3.642 1.00 17.71 223 CA ASN A 31 9.196 25.960−3.419 1.00 15.27 224 CB ASN A 31 9.347 27.009 −4.532 1.00 15.19 225 CGASN A 31 9.730 26.380 −5.894 1.00 19.59 226 OD1 ASN A 31 10.574 25.451−5.969 1.00 21.13 227 ND2 ASN A 31 9.134 26.918 −6.969 1.00 18.82 228 CASN A 31 9.208 26.685 −2.050 1.00 14.86 229 O ASN A 31 10.204 26.632−1.334 1.00 17.77 230 N ILE A 32 8.101 27.357 −1.743 1.00 19.65 231 CAILE A 32 8.001 28.096 −0.485 1.00 15.20 232 CB A ILE A 32 6.812 29.111−0.495 0.50 17.15 233 CB B ILE A 32 6.701 28.953 −0.500 0.50 14.78 234CG2A ILE A 32 5.490 28.426 −0.375 0.50 19.36 235 CG2B ILE A 32 5.46828.112 −0.368 0.50 23.40 236 CG1A ILE A 32 7.040 30.127 0.644 0.50 18.07237 CG1B ILE A 32 6.797 29.987 0.609 0.50 21.16 238 CD1A ILE A 32 6.22831.417 0.520 0.50 15.99 239 CD1B ILE A 32 7.978 30.835 0.383 0.50 19.15240 C ILE A 32 7.989 27.143 0.727 1.00 16.46 241 O ILE A 32 8.619 27.4371.757 1.00 15.29 242 N LYS A 33 7.332 25.998 0.591 1.00 17.77 243 CA LYSA 33 7.309 25.048 1.743 1.00 16.20 244 CB LYS A 33 6.261 23.944 1.5261.00 13.11 245 CG LYS A 33 4.798 24.446 1.720 1.00 14.90 246 CD LYS A 333.750 23.335 1.630 1.00 15.37 247 CE LYS A 33 3.503 22.844 0.200 1.0018.69 248 NZ LYS A 33 2.494 21.745 0.216 1.00 22.36 249 C LYS A 33 8.71524.549 2.031 1.00 18.54 250 O LYS A 33 9.101 24.325 3.200 1.00 16.33 251N LYS A 34 9.521 24.317 0.983 1.00 17.44 252 CA LYS A 34 10.901 23.9301.190 1.00 15.42 253 CB LYS A 34 11.526 23.571 −0.171 1.00 19.61 254 CGLYS A 34 12.900 23.000 −0.095 1.00 26.10 255 CD LYS A 34 13.498 22.704−1.485 1.00 29.86 256 CE LYS A 34 12.682 21.719 −2.274 1.00 27.95 257 NZLYS A 34 13.503 21.212 −3.424 1.00 38.16 258 C LYS A 34 11.690 25.0471.883 1.00 17.26 259 O LYS A 34 12.504 24.778 2.749 1.00 16.84 260 N GLUA 35 11.505 26.317 1.492 1.00 14.62 261 CA GLU A 35 12.208 27.398 2.1611.00 16.43 262 CB GLU A 35 11.855 28.761 1.577 1.00 15.39 263 CG GLU A35 12.379 29.019 0.228 1.00 17.59 264 CD GLU A 35 12.187 30.512 −0.0871.00 14.10 265 OE1 GLU A 35 13.022 31.331 0.398 1.00 15.22 266 OE2 GLU A35 11.194 30.810 −0.784 1.00 20.61 267 C GLU A 35 11.809 27.425 3.6431.00 14.00 268 O GLU A 35 12.651 27.666 4.506 1.00 15.78 269 N ILE A 3610.530 27.183 3.892 1.00 16.23 270 CA ILE A 36 10.039 27.185 5.292 1.0014.47 271 CB ILE A 36 8.510 27.040 5.308 1.00 13.60 272 CG2 ILE A 368.015 26.724 6.711 1.00 17.28 273 CG1 ILE A 36 7.914 28.343 4.763 1.0014.47 274 CD1 ILE A 36 6.428 28.274 4.541 1.00 16.94 275 C ILE A 3610.697 26.062 6.097 1.00 14.19 276 O ILE A 36 11.255 26.303 7.205 1.0014.89 277 N ALA A 37 10.720 24.884 5.482 1.00 15.18 278 CA ALA A 3711.319 23.723 6.148 1.00 15.59 279 CB ALA A 37 11.141 22.502 5.257 1.0017.71 280 C ALA A 37 12.784 23.958 6.483 1.00 16.91 281 O ALA A 3713.254 23.610 7.593 1.00 17.94 282 N GLU A 38 13.554 24.566 5.561 1.0015.64 283 CA GLU A 38 14.947 24.850 5.847 1.00 17.27 284 CB GLU A 3815.703 25.267 4.559 1.00 18.26 285 CG GLU A 38 15.871 24.166 3.536 1.0026.66 286 CD GLU A 38 16.713 22.998 4.047 1.00 25.35 287 OE1 GLU A 3817.656 23.241 4.833 1.00 27.87 288 OE2 GLU A 38 16.423 21.861 3.643 1.0030.64 289 C GLU A 38 15.189 25.874 6.927 1.00 18.13 290 O GLU A 3816.162 25.771 7.657 1.00 17.88 291 N ILE A 39 14.322 26.893 7.055 1.0016.32 292 CA ILE A 39 14.469 27.862 8.132 1.00 16.76 293 CB A ILE A 3913.596 29.114 7.940 0.50 17.98 294 CB B ILE A 39 13.552 29.099 7.9260.50 20.20 295 CG2A ILE A 39 13.419 29.872 9.275 0.50 15.47 296 CG2B ILEA 39 13.701 30.070 9.112 0.50 20.19 297 CG1A ILE A 39 14.290 30.0346.960 0.50 16.30 298 CG1B ILE A 39 13.891 29.783 6.599 0.50 21.26 299CD1A ILE A 39 13.373 31.005 6.323 0.50 12.77 300 CD1B ILE A 39 15.25530.429 6.550 0.50 23.48 301 C ILE A 39 14.101 27.176 9.485 1.00 14.27302 O ILE A 39 14.752 27.410 10.487 1.00 17.34 303 N LEU A 40 13.11126.294 9.466 1.00 15.11 304 CA LEU A 40 12.778 25.591 10.700 1.00 12.68305 CB LEU A 40 11.566 24.659 10.517 1.00 12.13 306 CG LEU A 40 10.25425.407 10.228 1.00 12.48 307 CD1 LEU A 40 9.122 24.392 10.022 1.00 16.06308 CD2 LEU A 40 9.898 26.311 11.408 1.00 17.03 309 C LEU A 40 13.99224.819 11.146 1.00 15.02 310 O LEU A 40 14.265 24.730 12.317 1.00 14.50311 N LYS A 41 14.716 24.243 10.183 1.00 13.32 312 CA LYS A 41 15.90823.470 10.524 1.00 14.52 313 CB LYS A 41 16.373 22.651 9.311 1.00 15.64314 CG LYS A 41 17.618 21.819 9.539 1.00 18.37 315 CD LYS A 41 18.01221.109 8.268 1.00 25.04 316 CE LYS A 41 19.355 20.435 8.470 1.00 28.16317 NZ LYS A 41 19.776 19.797 7.183 1.00 24.42 318 C LYS A 41 17.03824.386 10.993 1.00 17.40 319 O LYS A 41 17.623 24.180 12.049 1.00 21.49320 N SER A 42 17.337 25.429 10.213 1.00 17.40 321 CA SER A 42 18.45726.259 10.617 1.00 19.84 322 CB SER A 42 18.821 27.258 9.504 1.00 22.89323 OG SER A 42 17.798 28.213 9.318 1.00 26.40 324 C SER A 42 18.20926.949 11.933 1.00 21.31 325 O SER A 42 19.154 27.210 12.680 1.00 22.43326 N GLU A 43 16.936 27.199 12.261 1.00 19.93 327 CA GLU A 43 16.58127.857 13.509 1.00 17.11 328 CB GLU A 43 15.289 28.678 13.335 1.00 20.03329 CG GLU A 43 15.506 29.879 12.424 1.00 20.26 330 CD GLU A 43 16.46430.905 13.044 1.00 21.79 331 OE1 GLU A 43 16.183 31.346 14.183 1.0024.68 332 OE2 GLU A 43 17.460 31.260 12.356 1.00 24.12 333 C GLU A 4316.454 26.907 14.685 1.00 19.29 334 O GLU A 43 16.111 27.309 15.804 1.0021.07 335 N GLY A 44 16.708 25.625 14.410 1.00 18.95 336 CA GLY A 4416.684 24.647 15.485 1.00 18.08 337 C GLY A 44 15.331 24.095 15.866 1.0020.18 338 O GLY A 44 15.224 23.368 16.853 1.00 22.41 339 N PHE A 4514.292 24.392 15.090 1.00 16.56 340 CA PHE A 45 12.976 23.887 15.4661.00 16.87 341 CB PHE A 45 11.905 24.822 14.943 1.00 12.09 342 CG PHE A45 11.759 26.075 15.751 1.00 13.00 343 CD1 PHE A 45 11.169 26.036 17.0041.00 12.05 344 CD2 PHE A 45 12.218 27.292 15.266 1.00 14.04 345 CE1 PHEA 45 11.036 27.199 17.769 1.00 14.85 346 CE2 PHE A 45 12.090 28.45716.027 1.00 15.80 347 CZ PHE A 45 11.495 28.398 17.271 1.00 13.65 348 CPHE A 45 12.704 22.468 15.003 1.00 18.86 349 O PHE A 45 11.857 21.79715.567 1.00 17.57 350 N ILE A 46 13.335 22.059 13.899 1.00 16.30 351 CAILE A 46 13.224 20.683 13.456 1.00 17.57 352 CB ILE A 46 12.405 20.48912.157 1.00 13.61 353 CG2 ILE A 46 10.982 20.969 12.347 1.00 14.82 354CG1 ILE A 46 13.105 21.175 10.985 1.00 16.03 355 CD1 ILE A 46 12.43720.868 9.686 1.00 17.25 356 C ILE A 46 14.633 20.155 13.262 1.00 16.90357 O ILE A 46 15.608 20.926 13.169 1.00 17.77 358 N LYS A 47 14.75418.840 13.175 1.00 17.55 359 CA LYS A 47 16.050 18.200 13.042 1.00 20.67360 CB LYS A 47 15.916 16.801 13.653 1.00 22.04 361 CG LYS A 47 17.16715.986 13.857 1.00 34.96 362 CD LYS A 47 16.813 14.776 14.737 1.00 40.91363 CE LYS A 47 18.049 14.001 15.192 1.00 45.35 364 NZ LYS A 47 17.68912.841 16.081 1.00 47.44 365 C LYS A 47 16.587 18.137 11.627 1.00 23.96366 O LYS A 47 17.791 18.352 11.410 1.00 27.25 367 N ASN A 48 15.72417.862 10.660 1.00 23.14 368 CA ASN A 48 16.204 17.780 9.277 1.00 23.76369 CB ASN A 48 17.093 16.533 9.136 1.00 28.30 370 CG ASN A 48 17.72516.427 7.773 1.00 33.93 371 OD1 ASN A 48 18.184 17.433 7.219 1.00 35.73372 ND2 ASN A 48 17.758 15.209 7.223 1.00 36.71 373 C ASN A 48 15.05517.742 8.283 1.00 25.78 374 O ASN A 48 13.897 17.606 8.684 1.00 18.82375 N VAL A 49 15.387 17.875 6.990 1.00 20.75 376 CA VAL A 49 14.41817.827 5.891 1.00 20.69 377 CB VAL A 49 14.117 19.222 5.268 1.00 22.40378 CG1 VAL A 49 12.892 19.144 4.264 1.00 21.21 379 CG2 VAL A 49 13.92420.230 6.368 1.00 24.41 380 C VAL A 49 15.049 17.019 4.783 1.00 21.17381 O VAL A 49 16.189 17.291 4.415 1.00 28.56 382 N GLU A 50 14.30916.058 4.262 1.00 20.50 383 CA GLU A 50 14.783 15.246 3.130 1.00 22.14384 CB GLU A 50 14.761 13.754 3.486 1.00 24.09 385 CG GLU A 50 15.95213.292 4.274 1.00 29.46 386 CD GLU A 50 15.883 11.830 4.657 1.00 31.31387 OE1 GLU A 50 16.876 11.335 5.234 1.00 38.72 388 OE2 GLU A 50 14.83811.187 4.405 1.00 31.03 389 C GLU A 50 13.787 15.497 1.994 1.00 23.91390 O GLU A 50 12.589 15.669 2.233 1.00 20.50 391 N TYR A 51 14.28115.482 0.747 1.00 26.16 392 CA TYR A 51 13.432 15.676 −0.432 1.00 22.90393 CB TYR A 51 14.198 16.524 −1.454 1.00 24.90 394 CG TYR A 51 14.61617.903 −0.958 1.00 29.44 395 CD1 TYR A 51 15.629 18.620 −1.617 1.0033.16 396 CE1 TYR A 51 16.051 19.883 −1.158 1.00 31.21 397 CD2 TYR A 5114.020 18.489 0.172 1.00 32.63 398 CE2 TYR A 51 14.432 19.746 0.648 1.0029.86 399 CZ TYR A 51 15.453 20.435 −0.022 1.00 37.58 400 OH TYR A 5115.918 21.647 0.458 1.00 39.41 401 C TYR A 51 13.136 14.263 −0.982 1.0021.94 402 O TYR A 51 14.049 13.483 −1.173 1.00 27.59 403 N VAL A 5211.861 13.956 −1.220 1.00 21.78 404 CA VAL A 52 11.417 12.645 −1.6531.00 26.05 405 CB VAL A 52 10.458 12.039 −0.556 1.00 25.02 406 CG1 VAL A52 9.963 10.670 −0.928 1.00 28.46 407 CG2 VAL A 52 11.171 11.989 0.7811.00 29.62 408 C VAL A 52 10.667 12.687 −2.982 1.00 22.77 409 O VAL A 529.787 13.492 −3.177 1.00 21.42 410 N GLU A 53 11.002 11.783 −3.900 1.0025.82 411 CA GLU A 53 10.315 11.722 −5.182 1.00 24.93 412 CB GLU A 5311.183 10.936 −6.170 1.00 31.27 413 CG GLU A 53 12.599 11.449 −6.2621.00 35.20 414 CD GLU A 53 13.443 10.666 −7.242 0.50 39.45 415 OE1 GLU A53 12.862 10.086 −8.184 0.50 39.39 416 OE2 GLU A 53 14.684 10.644 −7.0770.50 38.84 417 C GLU A 53 8.943 11.061 −5.081 1.00 26.25 418 O GLU A 538.701 10.201 −4.212 1.00 27.80 419 N ASP A 54 8.029 11.480 −5.945 1.0022.37 420 CA ASP A 54 6.694 10.889 −6.004 1.00 28.05 421 CB ASP A 545.725 11.540 −4.992 1.00 26.65 422 CG ASP A 54 5.247 12.911 −5.400 1.0027.40 423 OD1 ASP A 54 5.824 13.516 −6.325 1.00 26.17 424 OD2 ASP A 544.283 13.394 −4.767 1.00 30.42 425 C ASP A 54 6.229 11.023 −7.467 1.0026.89 426 O ASP A 54 7.054 11.330 −8.329 1.00 27.63 427 N ASP A 55 4.94810.786 −7.750 1.00 32.96 428 CA ASP A 55 4.440 10.860 −9.127 1.00 36.53429 CB ASP A 55 3.444 9.715 −9.347 1.00 39.57 430 CG ASP A 55 2.1729.876 −8.515 1.00 45.50 431 OD1 ASP A 55 2.252 10.429 −7.401 1.00 47.07432 OD2 ASP A 55 1.093 9.450 −8.972 1.00 48.67 433 C ASP A 55 3.78612.216 −9.453 1.00 38.03 434 O ASP A 55 2.973 12.349 −10.395 1.00 39.71435 N LYS A 56 4.152 13.226 −8.671 1.00 33.03 436 CA LYS A 56 3.63014.574 −8.827 1.00 31.69 437 CB LYS A 56 2.611 14.862 −7.713 1.00 33.79438 CG LYS A 56 1.376 13.938 −7.780 1.00 39.31 439 CD LYS A 56 0.46214.111 −6.564 1.00 41.42 440 CE LYS A 56 −0.552 12.982 −6.461 0.50 44.11441 NZ LYS A 56 −1.562 13.216 −5.374 0.50 44.17 442 C LYS A 56 4.81115.532 −8.745 1.00 32.28 443 O LYS A 56 5.744 15.446 −9.556 1.00 32.47444 N GLN A 57 4.822 16.426 −7.761 1.00 26.84 445 CA GLN A 57 5.94717.356 −7.690 1.00 25.59 446 CB GLN A 57 5.455 18.807 −7.854 1.00 28.56447 CG GLN A 57 4.630 19.349 −6.716 1.00 33.11 448 CD GLN A 57 4.08920.762 −7.032 1.00 41.66 449 OE1 GLN A 57 3.819 21.563 −6.126 1.00 40.37450 NE2 GLN A 57 3.933 21.063 −8.327 1.00 39.88 451 C GLN A 57 6.86917.228 −6.458 1.00 22.95 452 O GLN A 57 7.460 18.204 −6.003 1.00 24.47453 N GLY A 58 7.000 16.002 −5.954 1.00 22.17 454 CA GLY A 58 7.87115.743 −4.843 1.00 18.50 455 C GLY A 58 7.246 15.913 −3.473 1.00 19.05456 O GLY A 58 6.213 16.547 −3.300 1.00 18.74 457 N VAL A 59 7.93215.306 −2.522 1.00 19.84 458 CA VAL A 59 7.518 15.281 −1.122 1.00 21.94459 CB VAL A 59 7.141 13.809 −0.757 1.00 19.26 460 CG1 VAL A 59 7.32513.542 0.762 1.00 24.81 461 CG2 VAL A 59 5.699 13.552 −1.174 1.00 23.20462 C VAL A 59 8.615 15.811 −0.202 1.00 17.61 463 O VAL A 59 9.80615.744 −0.494 1.00 18.55 464 N LEU A 60 8.214 16.469 0.894 1.00 17.50465 CA LEU A 60 9.187 16.927 1.890 1.00 16.68 466 CB LEU A 60 8.91718.375 2.301 1.00 20.18 467 CG LEU A 60 8.949 19.386 1.164 1.00 19.12468 CD1 LEU A 60 8.627 20.755 1.751 1.00 21.10 469 CD2 LEU A 60 10.33519.432 0.535 1.00 22.00 470 C LEU A 60 9.027 16.068 3.147 1.00 14.21 471O LEU A 60 7.901 15.894 3.633 1.00 19.41 472 N ARG A 61 10.128 15.5083.620 1.00 16.80 473 CA ARG A 61 10.062 14.670 4.820 1.00 14.82 474 CBARG A 61 10.752 13.321 4.554 1.00 19.03 475 CG ARG A 61 10.862 12.4405.794 1.00 20.10 476 CD ARG A 61 11.600 11.148 5.423 1.00 21.67 477 NEARG A 61 10.792 10.381 4.498 1.00 25.73 478 CZ ARG A 61 11.312 9.6603.515 1.00 24.65 479 NH1 ARG A 61 12.623 9.638 3.365 1.00 26.59 480 NH2ARG A 61 10.517 8.958 2.713 1.00 23.07 481 C ARG A 61 10.764 15.4565.909 1.00 15.91 482 O ARG A 61 11.903 15.814 5.788 1.00 19.77 483 N LEUA 62 9.995 15.842 6.924 1.00 15.80 484 CA LEU A 62 10.540 16.626 8.0321.00 15.07 485 CB LEU A 62 9.526 17.710 8.412 1.00 14.09 486 CG A LEU A62 9.612 19.002 7.538 0.50 11.86 487 CG B LEU A 62 9.092 18.710 7.3130.50 19.47 488 CD1A LEU A 62 9.154 18.712 6.107 0.50 14.08 489 CD1B LEUA 62 8.156 19.737 7.881 0.50 15.45 490 CD2A LEU A 62 8.756 20.118 8.1330.50 10.22 491 CD2B LEU A 62 10.308 19.396 6.747 0.50 22.00 492 C LEU A62 10.755 15.708 9.237 1.00 13.03 493 O LEU A 62 9.854 14.957 9.588 1.0019.09 494 N PHE A 63 11.912 15.853 9.852 1.00 15.26 495 CA PHE A 6312.268 15.085 11.061 1.00 13.36 496 CB PHE A 63 13.692 14.580 10.9491.00 17.23 497 CG PHE A 63 13.838 13.490 9.935 1.00 26.02 498 CD1 PHE A63 13.993 13.809 8.587 1.00 24.64 499 CD2 PHE A 63 13.772 12.146 10.3221.00 25.41 500 CE1 PHE A 63 14.086 12.806 7.606 1.00 34.29 501 CE2 PHE A63 13.864 11.125 9.347 1.00 30.88 502 CZ PHE A 63 14.020 11.458 7.9921.00 31.24 503 C PHE A 63 12.129 16.041 12.232 1.00 16.16 504 O PHE A 6312.857 17.025 12.336 1.00 16.35 505 N LEU A 64 11.188 15.721 13.124 1.0012.15 506 CA LEU A 64 10.949 16.628 14.265 1.00 13.95 507 CB LEU A 649.560 16.375 14.800 1.00 16.05 508 CG LEU A 64 8.443 16.513 13.753 1.0015.55 509 CD1 LEU A 64 7.115 16.434 14.462 1.00 14.33 510 CD2 LEU A 648.494 17.868 12.999 1.00 18.42 511 C LEU A 64 11.995 16.495 15.341 1.0016.79 512 O LEU A 64 12.764 15.541 15.331 1.00 16.10 513 N LYS A 6512.018 17.455 16.268 1.00 14.93 514 CA LYS A 65 13.088 17.498 17.2731.00 16.15 515 CB LYS A 65 13.953 18.742 17.031 1.00 16.36 516 CG LYS A65 15.259 18.779 17.846 1.00 21.68 517 CD LYS A 65 16.138 19.944 17.4241.00 24.61 518 CE LYS A 65 17.404 20.003 18.254 1.00 33.12 519 NZ LYS A65 18.140 21.237 17.860 1.00 43.56 520 C LYS A 65 12.514 17.552 18.6711.00 13.82 521 O LYS A 65 11.563 18.310 18.941 1.00 13.61 522 N TYR A 6613.072 16.708 19.526 1.00 14.18 523 CA TYR A 66 12.679 16.640 20.9291.00 14.37 524 CB TYR A 66 12.023 15.288 21.224 1.00 12.63 525 CG TYR A66 10.835 15.085 20.291 1.00 13.29 526 CD1 TYR A 66 9.609 15.707 20.5381.00 13.69 527 CE1 TYR A 66 8.549 15.590 19.660 1.00 10.82 528 CD2 TYR A66 10.952 14.337 19.115 1.00 12.56 529 CE2 TYR A 66 9.886 14.225 18.2181.00 14.32 530 CZ TYR A 66 8.683 14.849 18.492 1.00 10.23 531 OH TYR A66 7.638 14.780 17.596 1.00 14.03 532 C TYR A 66 13.934 16.887 21.7161.00 17.42 533 O TYR A 66 15.024 16.485 21.323 1.00 18.85 534 N GLY A 6713.767 17.579 22.832 1.00 14.07 535 CA GLY A 67 14.908 17.936 23.6351.00 16.44 536 C GLY A 67 15.520 16.825 24.458 1.00 12.83 537 O GLY A 6715.195 15.612 24.419 1.00 14.24 538 N GLN A 68 16.444 17.296 25.294 1.0019.98 539 CA GLN A 68 17.198 16.425 26.143 1.00 18.84 540 CB GLN A 6818.177 17.301 26.948 1.00 23.70 541 CG GLN A 68 19.007 18.305 26.0741.00 24.68 542 CD GLN A 68 19.915 17.585 25.083 1.00 30.35 543 OE1 GLN A68 20.240 18.098 24.001 1.00 32.02 544 NE2 GLN A 68 20.316 16.394 25.4461.00 25.11 545 C GLN A 68 16.310 15.597 27.098 1.00 19.88 546 O GLN A 6816.651 14.507 27.503 1.00 20.76 547 N ASN A 69 15.154 16.139 27.467 1.0014.22 548 CA ASN A 69 14.203 15.412 28.340 1.00 12.44 549 CB ASN A 6913.869 16.247 29.555 1.00 10.77 550 CG ASN A 69 15.064 16.407 30.4311.00 10.57 551 OD1 ASN A 69 15.457 15.425 31.071 1.00 14.00 552 ND2 ASNA 69 15.697 17.569 30.412 1.00 12.98 553 C ASN A 69 12.912 15.129 27.5701.00 12.79 554 O ASN A 69 11.825 14.974 28.173 1.00 14.19 555 N ASP A 7013.100 14.917 26.276 1.00 11.79 556 CA ASP A 70 12.025 14.595 25.3131.00 12.02 557 CB ASP A 70 11.389 13.228 25.621 1.00 17.75 558 CG ASP A70 12.406 12.087 25.591 1.00 19.88 559 OD1 ASP A 70 12.497 11.343 26.6041.00 23.44 560 OD2 ASP A 70 13.099 11.949 24.563 1.00 21.00 561 C ASP A70 10.937 15.657 25.224 1.00 13.39 562 O ASP A 70 9.861 15.382 24.6661.00 13.36 563 N GLU A 71 11.201 16.863 25.704 1.00 10.62 564 CA GLU A71 10.242 17.938 25.548 1.00 10.37 565 CB GLU A 71 10.604 19.104 26.5111.00 14.47 566 CG GLU A 71 11.821 19.909 26.133 1.00 14.73 567 CD GLU A71 13.156 19.327 26.526 1.00 14.61 568 OE1 GLU A 71 13.331 18.126 26.7891.00 12.82 569 OE2 GLU A 71 14.102 20.160 26.520 1.00 27.36 570 C GLU A71 10.200 18.408 24.092 1.00 12.85 571 O GLU A 71 11.197 18.298 23.3551.00 13.50 572 N ARG A 72 9.047 18.872 23.638 1.00 13.46 573 CA ARG A 728.959 19.300 22.236 1.00 12.06 574 CB ARG A 72 7.489 19.429 21.832 1.0014.51 575 CG ARG A 72 6.665 18.136 22.031 1.00 13.23 576 CD ARG A 725.223 18.386 21.673 1.00 13.43 577 NE ARG A 72 4.374 17.226 21.926 1.0011.18 578 CZ ARG A 72 3.848 16.887 23.092 1.00 11.42 579 NH1 ARG A 724.113 17.649 24.169 1.00 13.06 580 NH2 ARG A 72 3.021 15.824 23.182 1.0013.37 581 C ARG A 72 9.660 20.615 22.011 1.00 11.47 582 O ARG A 72 9.36121.575 22.711 1.00 13.15 583 N VAL A 73 10.534 20.664 21.008 1.00 13.86584 CA VAL A 73 11.256 21.876 20.721 1.00 14.77 585 CB VAL A 73 12.44821.548 19.821 1.00 15.31 586 CG1 VAL A 73 13.058 22.833 19.241 1.0020.54 587 CG2 VAL A 73 13.489 20.762 20.643 1.00 15.55 588 C VAL A 7310.272 22.904 20.153 1.00 16.77 589 O VAL A 73 10.422 24.086 20.381 1.0015.01 590 N ILE A 74 9.272 22.452 19.389 1.00 14.14 591 CA ILE A 748.235 23.348 18.905 1.00 12.14 592 CB ILE A 74 7.677 22.887 17.529 1.0011.54 593 CG2 ILE A 74 6.406 23.691 17.186 1.00 12.82 594 CG1 ILE A 748.753 23.086 16.462 1.00 13.81 595 CD1 ILE A 74 8.334 22.451 15.075 1.0012.99 596 C ILE A 74 7.066 23.344 19.903 1.00 13.54 597 O ILE A 74 6.57922.289 20.291 1.00 15.74 598 N THR A 75 6.680 24.514 20.382 1.00 12.14599 CA THR A 75 5.510 24.628 21.230 1.00 13.84 600 CB THR A 75 5.73125.709 22.300 1.00 12.46 601 OG1 THR A 75 6.743 25.218 23.179 1.00 15.45602 CG2 THR A 75 4.478 25.976 23.111 1.00 18.14 603 C THR A 75 4.29724.916 20.337 1.00 14.98 604 O THR A 75 3.187 24.353 20.522 1.00 17.04605 N GLY A 76 4.463 25.826 19.375 1.00 11.66 606 CA GLY A 76 3.34326.123 18.507 1.00 12.65 607 C GLY A 76 3.684 26.762 17.177 1.00 12.76608 O GLY A 76 4.806 27.221 16.964 1.00 13.34 609 N LEU A 77 2.71326.755 16.279 1.00 12.96 610 CA LEU A 77 2.888 27.371 14.964 1.00 12.42611 CB LEU A 77 3.072 26.322 13.842 1.00 14.28 612 CG LEU A 77 4.13225.265 14.107 1.00 12.84 613 CD1 LEU A 77 3.401 24.050 14.640 1.00 17.27614 CD2 LEU A 77 4.956 24.885 12.857 1.00 15.61 615 C LEU A 77 1.58228.080 14.667 1.00 14.97 616 O LEU A 77 0.487 27.554 14.965 1.00 18.39617 N LYS A 78 1.655 29.236 14.041 1.00 10.89 618 CA LYS A 78 0.41629.955 13.757 1.00 10.92 619 CB LYS A 78 0.172 31.055 14.804 1.00 12.46620 CG LYS A 78 −1.154 31.763 14.642 1.00 15.96 621 CD LYS A 78 −1.35032.790 15.742 1.00 22.89 622 CE LYS A 78 −2.622 33.607 15.540 1.00 29.30623 NZ LYS A 78 −2.558 34.367 14.253 1.00 38.34 624 C LYS A 78 0.51330.619 12.386 1.00 12.82 625 O LYS A 78 1.510 31.253 12.080 1.00 12.93626 N ARG A 79 −0.475 30.382 11.519 1.00 11.89 627 CA ARG A 79 −0.49431.037 10.220 1.00 10.36 628 CB ARG A 79 −1.506 30.340 9.317 1.00 11.45629 CG ARG A 79 −1.630 30.922 7.924 1.00 10.70 630 CD ARG A 79 −0.42830.458 7.065 1.00 11.44 631 NE ARG A 79 −0.709 30.696 5.643 1.00 10.29632 CZ ARG A 79 −0.041 31.473 4.800 1.00 11.86 633 NH1 ARG A 79 1.00332.198 5.180 1.00 10.82 634 NH2 ARG A 79 −0.424 31.510 3.506 1.00 13.18635 C ARG A 79 −0.898 32.485 10.467 1.00 10.70 636 O ARG A 79 −1.84432.761 11.213 1.00 12.98 637 N ILE A 80 −0.207 33.439 9.816 1.00 9.68638 CA ILE A 80 −0.498 34.872 10.004 1.00 11.10 639 CB ILE A 80 0.81635.639 10.398 1.00 10.52 640 CG2 ILE A 80 0.556 37.170 10.588 1.00 10.50641 CG1 ILE A 80 1.316 35.053 11.733 1.00 11.58 642 CD1 ILE A 80 0.35935.297 12.974 1.00 15.29 643 C ILE A 80 −1.136 35.413 8.772 1.00 12.17644 O ILE A 80 −2.353 35.571 8.728 1.00 11.92 645 N SER A 81 −0.34435.677 7.729 1.00 10.37 646 CA SER A 81 −0.904 36.120 6.481 1.00 8.76647 CB SER A 81 0.254 36.562 5.536 1.00 8.86 648 OG SER A 81 −0.27737.045 4.338 1.00 12.21 649 C SER A 81 −1.681 34.906 5.922 1.00 10.94650 O SER A 81 −1.324 33.758 6.143 1.00 11.56 651 N LYS A 82 −2.72735.198 5.145 1.00 11.16 652 CA LYS A 82 −3.548 34.134 4.538 1.00 12.55653 CB LYS A 82 −4.784 33.856 5.398 1.00 14.71 654 CG LYS A 82 −4.39633.348 6.774 1.00 12.80 655 CD LYS A 82 −5.621 33.057 7.701 1.00 18.06656 CE LYS A 82 −5.073 32.703 9.096 1.00 21.61 657 NZ LYS A 82 −6.12032.420 10.082 1.00 32.93 658 C LYS A 82 −3.989 34.584 3.184 1.00 12.61659 O LYS A 82 −3.998 35.755 2.894 1.00 13.82 660 N PRO A 83 −4.35733.629 2.302 1.00 14.58 661 CD PRO A 83 −4.305 32.155 2.405 1.00 17.91662 CA PRO A 83 −4.794 34.083 0.974 1.00 14.56 663 CB PRO A 83 −5.08832.760 0.231 1.00 15.53 664 CG PRO A 83 −4.146 31.756 0.948 1.00 16.19665 C PRO A 83 −6.014 34.979 1.077 1.00 14.00 666 O PRO A 83 −6.96434.658 1.776 1.00 16.77 667 N GLY A 84 −5.918 36.115 0.383 1.00 15.18668 CA GLY A 84 −6.980 37.103 0.402 1.00 15.76 669 C GLY A 84 −7.02237.943 1.657 1.00 15.78 670 O GLY A 84 −7.873 38.827 1.783 1.00 16.65671 N LEU A 85 −6.110 37.681 2.602 1.00 14.27 672 CA LEU A 85 −6.07538.416 3.879 1.00 12.30 673 CB LEU A 85 −6.739 37.573 4.960 1.00 13.25674 CG LEU A 85 −8.234 37.251 4.729 1.00 13.75 675 CD1 LEU A 85 −8.63936.120 5.626 1.00 15.04 676 CD2 LEU A 85 −9.052 38.489 5.038 1.00 18.34677 C LEU A 85 −4.570 38.552 4.204 1.00 11.17 678 O LEU A 85 −4.10238.096 5.231 1.00 12.96 679 N ARG A 86 −3.890 39.225 3.306 1.00 13.55680 CA ARG A 86 −2.425 39.357 3.426 1.00 11.95 681 CB ARG A 86 −1.85939.999 2.156 1.00 14.49 682 CG ARG A 86 −0.344 40.227 2.136 1.00 17.98683 CD ARG A 86 0.236 40.268 0.644 1.00 17.43 684 NE ARG A 86 1.67040.580 0.600 1.00 18.04 685 CZ ARG A 86 2.156 41.811 0.538 1.00 21.23686 NH1 ARG A 86 1.322 42.858 0.504 1.00 22.22 687 NH2 ARG A 86 3.46842.009 0.510 1.00 18.96 688 C ARG A 86 −2.042 40.197 4.606 1.00 13.56689 O ARG A 86 −2.766 41.169 4.971 1.00 14.01 690 N VAL A 87 −0.92639.783 5.238 1.00 9.25 691 CA VAL A 87 −0.338 40.559 6.339 1.00 9.09 692CB VAL A 87 −0.229 39.735 7.584 1.00 8.47 693 CG1 VAL A 87 0.553 40.4878.676 1.00 12.12 694 CG2 VAL A 87 −1.661 39.516 8.105 1.00 11.24 695 CVAL A 87 1.077 40.956 5.919 1.00 10.79 696 O VAL A 87 1.913 40.081 5.7391.00 10.09 697 N TYR A 88 1.297 42.255 5.750 1.00 15.79 698 CA TYR A 882.605 42.825 5.405 1.00 15.47 699 CB TYR A 88 2.498 43.608 4.112 1.0012.62 700 CG TYR A 88 3.703 44.530 3.834 1.00 17.48 701 CD1 TYR A 884.906 44.009 3.309 1.00 14.80 702 CE1 TYR A 88 6.012 44.852 3.105 1.0018.42 703 CD2 TYR A 88 3.642 45.892 4.144 1.00 20.80 704 CE2 TYR A 884.735 46.720 3.944 1.00 20.23 705 CZ TYR A 88 5.907 46.198 3.427 1.0020.55 706 OH TYR A 88 6.987 47.068 3.190 1.00 24.23 707 C TYR A 88 3.05743.742 6.518 1.00 16.01 708 O TYR A 88 2.284 44.560 7.020 1.00 15.46 709N ALA A 89 4.293 43.540 6.975 1.00 11.50 710 CA ALA A 89 4.864 44.3958.011 1.00 10.38 711 CB ALA A 89 5.488 43.586 9.101 1.00 14.07 712 C ALAA 89 5.936 45.230 7.349 1.00 16.04 713 O ALA A 89 6.851 44.668 6.7481.00 16.15 714 N LYS A 90 5.822 46.562 7.419 1.00 16.05 715 CA LYS A 906.889 47.351 6.860 1.00 18.86 716 CB LYS A 90 6.501 48.834 6.782 1.0017.60 717 CG LYS A 90 6.214 49.437 8.122 1.00 21.58 718 CD LYS A 906.033 50.969 7.971 1.00 33.81 719 CE LYS A 90 4.588 51.376 8.089 1.0040.08 720 NZ LYS A 90 4.469 52.869 8.168 1.00 44.32 721 C LYS A 90 8.09847.144 7.787 1.00 17.54 722 O LYS A 90 7.966 46.636 8.904 1.00 16.76 723N ALA A 91 9.278 47.576 7.337 1.00 16.64 724 CA ALA A 91 10.479 47.3668.128 1.00 18.67 725 CB ALA A 91 11.655 48.041 7.427 1.00 18.91 726 CALA A 91 10.442 47.765 9.606 1.00 18.05 727 O ALA A 91 10.855 47.00110.488 1.00 17.91 728 N SER A 92 9.917 48.942 9.896 1.00 23.72 729 CASER A 92 9.857 49.403 11.285 1.00 23.89 730 CB SER A 92 9.585 50.92611.318 1.00 26.05 731 OG SER A 92 8.330 51.249 10.729 1.00 26.98 732 CSER A 92 8.804 48.705 12.137 1.00 25.38 733 O SER A 92 8.788 48.88913.352 1.00 27.23 734 N GLU A 93 7.916 47.913 11.516 1.00 20.29 735 CAGLU A 93 6.842 47.260 12.254 1.00 21.56 736 CB GLU A 93 5.502 47.56011.571 1.00 19.70 737 CG GLU A 93 5.106 49.036 11.582 1.00 28.45 738 CDGLU A 93 5.101 49.629 12.970 1.00 29.50 739 OE1 GLU A 93 4.379 49.09613.837 1.00 26.15 740 OE2 GLU A 93 5.827 50.621 13.210 1.00 39.50 741 CGLU A 93 7.049 45.751 12.307 1.00 17.97 742 O GLU A 93 6.153 45.01212.704 1.00 18.18 743 N MET A 94 8.238 45.313 11.919 1.00 18.42 744 CAMET A 94 8.559 43.884 11.902 1.00 15.60 745 CB MET A 94 10.022 43.73811.450 1.00 17.32 746 CG MET A 94 10.506 42.298 11.261 1.00 14.83 747 SDMET A 94 9.488 41.315 10.140 1.00 15.25 748 CE MET A 94 9.452 42.2978.736 1.00 13.31 749 C MET A 94 8.303 43.333 13.298 1.00 18.99 750 O META 94 9.006 43.707 14.242 1.00 21.10 751 N PRO A 95 7.276 42.467 13.4621.00 16.98 752 CD PRO A 95 6.432 41.893 12.376 1.00 15.20 753 CA PRO A95 6.904 41.888 14.764 1.00 16.05 754 CB PRO A 95 5.548 41.244 14.4711.00 18.87 755 CG PRO A 95 5.759 40.680 13.042 1.00 18.12 756 C PRO A 957.883 40.914 15.385 1.00 19.74 757 O PRO A 95 8.725 40.319 14.679 1.0018.41 758 N LYS A 96 7.829 40.810 16.719 1.00 20.86 759 CA LYS A 968.642 39.817 17.439 1.00 15.85 760 CB LYS A 96 9.493 40.412 18.582 1.0020.02 761 CG LYS A 96 10.828 41.009 18.113 1.00 23.65 762 CD LYS A 9611.659 41.458 19.306 1.00 26.92 763 CE LYS A 96 13.005 41.929 18.8521.00 31.82 764 NZ LYS A 96 13.814 42.480 19.977 1.00 38.15 765 C LYS A96 7.640 38.861 18.013 1.00 17.68 766 O LYS A 96 6.505 39.237 18.3271.00 20.06 767 N VAL A 97 8.048 37.599 18.089 1.00 15.40 768 CA VAL A 977.198 36.538 18.615 1.00 13.12 769 CB VAL A 97 7.302 35.297 17.676 1.0014.86 770 CG1 VAL A 97 6.486 34.125 18.179 1.00 18.80 771 CG2 VAL A 976.754 35.714 16.258 1.00 17.83 772 C VAL A 97 7.750 36.254 20.009 1.0016.78 773 O VAL A 97 8.926 35.882 20.157 1.00 16.90 774 N LEU A 98 6.87336.385 21.019 1.00 18.18 775 CA LEU A 98 7.280 36.214 22.436 1.00 19.32776 CB LEU A 98 7.452 34.717 22.818 1.00 24.20 777 CG LEU A 98 6.20433.827 22.670 1.00 25.60 778 CD1 LEU A 98 6.543 32.388 23.109 1.00 22.47779 CD2 LEU A 98 5.032 34.418 23.497 1.00 22.24 780 C LEU A 98 8.53437.002 22.768 1.00 22.57 781 O LEU A 98 9.491 36.489 23.376 1.00 21.80782 N ASN A 99 8.528 38.265 22.346 1.00 20.95 783 CA ASN A 99 9.63939.167 22.588 1.00 21.68 784 CB ASN A 99 9.751 39.444 24.102 1.00 20.16785 CG ASN A 99 8.731 40.461 24.605 1.00 28.35 786 OD1 ASN A 99 8.64540.709 25.808 1.00 29.89 787 ND2 ASN A 99 7.955 41.054 23.699 1.00 22.63788 C ASN A 99 10.985 38.682 22.028 1.00 21.34 789 O ASN A 99 12.03739.161 22.432 1.00 22.61 790 N GLY A 100 10.971 37.747 21.066 1.00 16.11791 CA GLY A 100 12.221 37.306 20.487 1.00 18.10 792 C GLY A 100 12.48635.832 20.738 1.00 16.81 793 O GLY A 100 13.424 35.276 20.175 1.00 18.53794 N LEU A 101 11.650 35.186 21.553 1.00 18.12 795 CA LEU A 101 11.87733.774 21.866 1.00 17.08 796 CB LEU A 101 11.258 33.369 23.223 1.0016.32 797 CG LEU A 101 11.960 33.969 24.458 1.00 19.19 798 CD1 LEU A 10111.193 33.475 25.709 1.00 21.03 799 CD2 LEU A 101 13.398 33.542 24.5431.00 23.46 800 C LEU A 101 11.378 32.857 20.773 1.00 16.32 801 O LEU A101 11.834 31.726 20.668 1.00 16.93 802 N GLY A 102 10.406 33.340 19.9911.00 15.32 803 CA GLY A 102 9.966 32.567 18.850 1.00 11.91 804 C GLY A102 10.426 33.317 17.598 1.00 14.50 805 O GLY A 102 11.206 34.227 17.6861.00 14.08 806 N ILE A 103 9.992 32.878 16.428 1.00 11.41 807 CA ILE A103 10.360 33.553 15.196 1.00 10.51 808 CB ILE A 103 11.344 32.71614.297 1.00 12.15 809 CG2 ILE A 103 12.684 32.538 15.031 1.00 15.59 810CG1 ILE A 103 10.759 31.343 13.931 1.00 13.72 811 CD1 ILE A 103 11.70430.512 13.005 1.00 15.76 812 C ILE A 103 9.142 33.780 14.332 1.00 11.21813 O ILE A 103 8.162 33.046 14.406 1.00 13.44 814 N ALA A 104 9.20634.835 13.529 1.00 9.11 815 CA ALA A 104 8.196 35.037 12.480 1.00 11.44816 CB ALA A 104 7.731 36.490 12.379 1.00 12.52 817 C ALA A 104 8.93734.660 11.192 1.00 14.21 818 O ALA A 104 10.139 34.916 11.030 1.00 12.74819 N LEU A 105 8.229 34.008 10.271 1.00 10.13 820 CA LEU A 105 8.82033.679 8.953 1.00 9.95 821 CB LEU A 105 8.331 32.332 8.470 1.00 9.52 822CG LEU A 105 8.710 31.200 9.432 1.00 17.45 823 CD1 LEU A 105 8.10429.878 8.932 1.00 19.68 824 CD2 LEU A 105 10.206 31.078 9.536 1.00 23.41825 C LEU A 105 8.283 34.800 8.034 1.00 9.90 826 O LEU A 105 7.09935.097 7.995 1.00 10.55 827 N VAL A 106 9.221 35.455 7.327 1.00 9.62 828CA VAL A 106 8.912 36.651 6.531 1.00 10.35 829 CB VAL A 106 9.725 37.8457.062 1.00 12.20 830 CG1 VAL A 106 9.395 39.124 6.314 1.00 9.56 831 CG2VAL A 106 9.476 37.991 8.604 1.00 12.36 832 C VAL A 106 9.251 36.4255.066 1.00 12.29 833 O VAL A 106 10.368 36.045 4.741 1.00 11.23 834 NSER A 107 8.272 36.627 4.169 1.00 10.90 835 CA SER A 107 8.526 36.4432.729 1.00 12.19 836 CB SER A 107 7.240 36.034 1.994 1.00 14.23 837 OGSER A 107 7.570 35.730 0.639 1.00 16.39 838 C SER A 107 8.985 37.7822.187 1.00 10.58 839 O SER A 107 8.270 38.789 2.292 1.00 11.06 840 N THRA 108 10.204 37.818 1.621 1.00 10.16 841 CA THR A 108 10.782 39.0491.128 1.00 10.99 842 CB THR A 108 12.017 39.513 1.947 1.00 10.30 843 OG1THR A 108 13.142 38.642 1.616 1.00 11.31 844 CG2 THR A 108 11.749 39.4453.451 1.00 11.47 845 C THR A 108 11.257 38.891 −0.286 1.00 9.32 846 OTHR A 108 11.201 37.803 −0.875 1.00 11.44 847 N SER A 109 11.750 40.012−0.856 1.00 10.95 848 CA SER A 109 12.223 39.937 −2.247 1.00 12.01 849CB SER A 109 12.499 41.334 −2.759 1.00 13.38 850 OG SER A 109 13.52241.854 −1.944 1.00 19.19 851 C SER A 109 13.462 39.058 −2.426 1.00 11.60852 O SER A 109 13.771 38.660 −3.551 1.00 12.69 853 N GLU A 110 14.12338.683 −1.328 1.00 11.99 854 CA GLU A 110 15.301 37.802 −1.372 1.0014.00 855 CB A GLU A 110 16.487 38.458 −0.640 0.50 15.92 856 CB B GLU A110 16.447 38.405 −0.513 0.50 13.21 857 CG A GLU A 110 17.317 39.438−1.538 0.50 20.73 858 CG B GLU A 110 16.924 39.808 −0.907 0.50 12.55 859CD A GLU A 110 18.087 38.755 −2.692 0.50 20.98 860 CD B GLU A 110 18.26440.237 −0.267 0.50 16.47 861 OE1A GLU A 110 17.423 38.218 −3.630 0.5014.75 862 OE1B GLU A 110 19.328 39.694 −0.639 0.50 20.77 863 OE2A GLU A110 19.368 38.735 −2.674 0.50 20.13 864 OE2B GLU A 110 18.247 41.1420.605 0.50 21.01 865 C GLU A 110 14.998 36.391 −0.844 1.00 15.80 866 OGLU A 110 15.924 35.574 −0.683 1.00 17.76 867 N GLY A 111 13.708 36.067−0.653 1.00 11.83 868 CA GLY A 111 13.328 34.772 −0.100 1.00 13.35 869 CGLY A 111 12.771 34.903 1.322 1.00 10.68 870 O GLY A 111 12.666 36.0141.881 1.00 11.13 871 N VAL A 112 12.470 33.747 1.924 1.00 10.43 872 CAVAL A 112 11.939 33.694 3.282 1.00 11.99 873 CB VAL A 112 11.179 32.3653.517 1.00 11.37 874 CG1 VAL A 112 10.583 32.363 4.913 1.00 14.43 875CG2 VAL A 112 10.018 32.256 2.519 1.00 11.74 876 C VAL A 112 13.09733.793 4.283 1.00 10.65 877 O VAL A 112 14.121 33.141 4.102 1.00 14.31878 N ILE A 113 12.919 34.676 5.252 1.00 11.14 879 CA ILE A 113 13.88534.942 6.300 1.00 12.82 880 CB ILE A 113 14.714 36.232 6.040 1.00 12.46881 CG2 ILE A 113 15.514 36.051 4.737 1.00 14.34 882 CG1 ILE A 11313.839 37.499 6.046 1.00 13.84 883 CD1 ILE A 113 14.689 38.841 5.8551.00 12.60 884 C ILE A 113 13.172 35.080 7.629 1.00 12.25 885 O ILE A113 11.940 35.138 7.670 1.00 12.19 886 N THR A 114 13.920 35.103 8.7271.00 11.55 887 CA THR A 114 13.271 35.294 10.024 1.00 12.41 888 CB THR A114 14.165 34.776 11.162 1.00 11.80 889 OG1 THR A 114 15.400 35.53011.176 1.00 15.64 890 CG2 THR A 114 14.494 33.307 10.927 1.00 14.91 891C THR A 114 13.080 36.791 10.297 1.00 11.81 892 O THR A 114 13.64737.683 9.603 1.00 11.26 893 N ASP A 115 12.274 37.124 11.291 1.00 11.36894 CA ASP A 115 12.113 38.521 11.660 1.00 10.96 895 CB ASP A 115 11.01738.718 12.737 1.00 12.92 896 CG ASP A 115 11.284 37.910 13.990 1.0014.65 897 OD1 ASP A 115 11.391 36.689 13.875 1.00 15.57 898 OD2 ASP A115 11.430 38.516 15.085 1.00 14.56 899 C ASP A 115 13.435 39.122 12.1451.00 12.23 900 O ASP A 115 13.668 40.271 11.888 1.00 13.08 901 N LYS A116 14.268 38.332 12.815 1.00 12.96 902 CA LYS A 116 15.574 38.83813.282 1.00 14.53 903 CB LYS A 116 16.274 37.743 14.104 1.00 16.96 904CG LYS A 116 17.641 38.212 14.659 1.00 24.00 905 CD LYS A 116 18.22637.192 15.611 1.00 25.03 906 CE LYS A 116 18.633 35.953 14.896 1.0038.30 907 NZ LYS A 116 19.573 36.227 13.785 1.00 42.73 908 C LYS A 11616.418 39.234 12.065 1.00 14.20 909 O LYS A 116 17.060 40.305 12.0371.00 15.23 910 N GLU A 117 16.416 38.400 11.035 1.00 14.02 911 CA GLU A117 17.200 38.697 9.836 1.00 11.91 912 CB GLU A 117 17.287 37.465 8.9561.00 12.83 913 CG GLU A 117 18.125 37.658 7.727 1.00 15.14 914 CD GLU A117 19.629 37.853 8.066 1.00 20.85 915 OE1 GLU A 117 20.090 37.378 9.1211.00 23.10 916 OE2 GLU A 117 20.312 38.479 7.263 1.00 21.25 917 C GLU A117 16.576 39.865 9.084 1.00 15.14 918 O GLU A 117 17.291 40.687 8.5091.00 14.51 919 N ALA A 118 15.236 39.972 9.067 1.00 12.70 920 CA ALA A118 14.617 41.104 8.406 1.00 11.31 921 CB ALA A 118 13.038 40.949 8.4281.00 12.66 922 C ALA A 118 15.021 42.426 9.092 1.00 12.16 923 O ALA A118 15.262 43.422 8.399 1.00 12.80 924 N ARG A 119 15.059 42.443 10.4111.00 13.29 925 CA ARG A 119 15.495 43.646 11.129 1.00 15.43 926 CB ARG A119 15.282 43.522 12.639 1.00 16.04 927 CG ARG A 119 13.807 43.60313.028 1.00 19.01 928 CD A ARG A 119 13.591 43.740 14.511 0.50 19.48 929CD B ARG A 119 13.719 43.584 14.582 0.50 20.49 930 NE A ARG A 119 13.82442.462 15.138 0.50 18.80 931 NE B ARG A 119 12.375 43.210 14.988 0.5021.60 932 CZ A ARG A 119 12.932 41.468 15.209 0.50 14.46 933 CZ B ARG A119 11.972 41.953 15.129 0.50 23.90 934 NH1A ARG A 119 11.689 41.59414.704 0.50 13.01 935 NH1B ARG A 119 12.826 40.949 14.943 0.50 23.65 936NH2A ARG A 119 13.317 40.329 15.745 0.50 15.29 937 NH2B ARG A 119 10.69741.697 15.336 0.50 23.44 938 C ARG A 119 16.954 43.948 10.843 1.00 16.59939 O ARG A 119 17.307 45.131 10.722 1.00 18.33 940 N LYS A 120 17.78342.913 10.695 1.00 16.72 941 CA LYS A 120 19.206 43.113 10.407 1.0017.81 942 CB LYS A 120 19.945 41.777 10.444 1.00 19.86 943 CG LYS A 12021.441 41.907 10.270 1.00 22.47 944 CD LYS A 120 22.127 40.605 10.5081.00 25.51 945 CE LYS A 120 23.622 40.805 10.517 1.00 29.10 946 NZ LYS A120 24.238 39.467 10.455 1.00 27.57 947 C LYS A 120 19.353 43.759 9.0491.00 19.84 948 O LYS A 120 20.127 44.721 8.886 1.00 20.84 949 N ARG A121 18.587 43.256 8.086 1.00 16.16 950 CA ARG A 121 18.597 43.788 6.7081.00 16.00 951 CB ARG A 121 18.041 42.747 5.732 1.00 14.54 952 CG ARG A121 18.815 41.472 5.727 1.00 14.40 953 CD ARG A 121 18.223 40.465 4.7671.00 15.26 954 NE ARG A 121 18.925 39.209 4.868 1.00 16.91 955 CZ ARG A121 18.747 38.187 4.039 1.00 17.71 956 NH1 ARG A 121 17.865 38.307 3.0351.00 17.28 957 NH2 ARG A 121 19.415 37.056 4.216 1.00 21.13 958 C ARG A121 17.788 45.066 6.557 1.00 15.53 959 O ARG A 121 17.820 45.672 5.4771.00 18.69 960 N ASN A 122 17.048 45.486 7.589 1.00 14.07 961 CA ASN A122 16.243 46.708 7.514 1.00 17.04 962 CB ASN A 122 17.137 47.955 7.2441.00 22.48 963 CG ASN A 122 18.320 48.072 8.239 1.00 29.06 964 OD1 ASN A122 18.130 48.029 9.454 1.00 28.68 965 ND2 ASN A 122 19.547 48.221 7.7031.00 27.29 966 C ASN A 122 15.150 46.621 6.464 1.00 18.23 967 O ASN A122 14.860 47.594 5.774 1.00 18.73 968 N VAL A 123 14.536 45.447 6.3411.00 16.71 969 CA VAL A 123 13.461 45.251 5.376 1.00 15.28 970 CB VAL A123 13.843 44.253 4.282 1.00 13.67 971 CG1 VAL A 123 15.122 44.801 3.5031.00 17.85 972 CG2 VAL A 123 14.122 42.824 4.878 1.00 13.19 973 C VAL A123 12.160 44.770 6.038 1.00 12.69 974 O VAL A 123 12.162 44.216 7.1321.00 17.06 975 N GLY A 124 11.069 44.998 5.329 1.00 17.32 976 CA GLY A124 9.793 44.462 5.785 1.00 15.85 977 C GLY A 124 9.432 43.252 4.9311.00 16.00 978 O GLY A 124 10.264 42.696 4.186 1.00 16.36 979 N GLY A125 8.182 42.775 5.037 1.00 10.61 980 CA GLY A 125 7.835 41.654 4.1921.00 9.89 981 C GLY A 125 6.506 41.030 4.638 1.00 9.46 982 O GLY A 1255.906 41.495 5.600 1.00 10.75 983 N GLU A 126 6.039 40.049 3.903 1.009.36 984 CA GLU A 126 4.803 39.356 4.277 1.00 9.61 985 CB GLU A 1264.271 38.551 3.071 1.00 11.09 986 CG GLU A 126 2.972 37.777 3.385 1.0010.61 987 CD A GLU A 126 2.484 36.896 2.225 0.50 12.54 988 CD B GLU A126 2.185 37.457 2.115 0.50 10.50 989 OE1A GLU A 126 1.489 36.172 2.4380.50 12.17 990 OE1B GLU A 126 1.219 36.688 2.239 0.50 11.10 991 OE2A GLUA 126 3.085 36.928 1.122 0.50 16.76 992 OE2B GLU A 126 2.520 37.9600.999 0.50 8.65 993 C GLU A 126 5.065 38.409 5.444 1.00 10.32 994 O GLUA 126 5.984 37.577 5.426 1.00 10.19 995 N ILE A 127 4.243 38.516 6.4961.00 8.30 996 CA ILE A 127 4.435 37.661 7.668 1.00 8.50 997 CB ILE A 1273.927 38.380 8.967 1.00 11.00 998 CG2 ILE A 127 4.258 37.485 10.202 1.0010.20 999 CG1 ILE A 127 4.566 39.791 9.075 1.00 9.94 1000 CD1 ILE A 1276.081 39.758 9.113 1.00 11.70 1001 C ILE A 127 3.659 36.378 7.442 1.0012.94 1002 O ILE A 127 2.459 36.309 7.583 1.00 12.22 1003 N ILE A 1284.385 35.338 7.127 1.00 8.16 1004 CA ILE A 128 3.788 34.069 6.756 1.008.43 1005 CB ILE A 128 4.893 33.088 6.162 1.00 11.68 1006 CG2 ILE A 1284.278 31.664 5.893 1.00 15.27 1007 CG1 ILE A 128 5.483 33.723 4.912 1.0014.92 1008 CD1 ILE A 128 6.709 32.916 4.404 1.00 15.70 1009 C ILE A 1283.225 33.362 7.969 1.00 11.10 1010 O ILE A 128 2.098 32.815 7.928 1.0011.36 1011 N ALA A 129 4.001 33.360 9.056 1.00 8.42 1012 CA ALA A 1293.651 32.517 10.190 1.00 11.31 1013 CB ALA A 129 3.886 31.030 9.831 1.0012.62 1014 C ALA A 129 4.538 32.857 11.358 1.00 11.70 1015 O ALA A 1295.573 33.471 11.188 1.00 10.52 1016 N TYR A 130 4.128 32.376 12.524 1.0012.71 1017 CA TYR A 130 4.912 32.503 13.772 1.00 11.06 1018 CB TYR A 1304.096 33.153 14.884 1.00 9.73 1019 CG TYR A 130 3.810 34.647 14.798 1.0013.43 1020 CD1 TYR A 130 2.929 35.276 15.743 1.00 13.93 1021 CE1 TYR A130 2.711 36.649 15.720 1.00 12.86 1022 CD2 TYR A 130 4.440 35.45313.850 1.00 13.69 1023 CE2 TYR A 130 4.206 36.814 13.815 1.00 12.21 1024CZ TYR A 130 3.361 37.403 14.744 1.00 14.07 1025 OH TYR A 130 3.16438.783 14.702 1.00 19.26 1026 C TYR A 130 5.197 31.077 14.232 1.00 12.061027 O TYR A 130 4.330 30.179 14.093 1.00 13.06 1028 N VAL A 131 6.38430.847 14.761 1.00 12.37 1029 CA VAL A 131 6.746 29.545 15.321 1.0010.90 1030 CB VAL A 131 7.705 28.725 14.383 1.00 12.13 1031 CG1 VAL A131 8.111 27.380 15.002 1.00 13.61 1032 CG2 VAL A 131 6.977 28.47213.036 1.00 13.82 1033 C VAL A 131 7.443 29.836 16.639 1.00 12.68 1034 OVAL A 131 8.233 30.741 16.707 1.00 12.17 1035 N TRP A 132 7.148 29.06017.688 1.00 11.81 1036 CA TRP A 132 7.791 29.277 18.979 1.00 10.13 1037CB TRP A 132 6.984 30.310 19.794 1.00 12.88 1038 CG TRP A 132 5.53329.885 20.176 1.00 14.49 1039 CD2 TRP A 132 4.353 29.986 19.348 1.0013.75 1040 CE2 TRP A 132 3.279 29.441 20.090 1.00 18.93 1041 CE3 TRP A132 4.108 30.484 18.058 1.00 15.41 1042 CD1 TRP A 132 5.129 29.30621.355 1.00 15.76 1043 NE1 TRP A 132 3.787 29.049 21.303 1.00 18.78 1044CZ2 TRP A 132 1.975 29.369 19.589 1.00 19.22 1045 CZ3 TRP A 132 2.80330.412 17.548 1.00 18.59 1046 CH2 TRP A 132 1.748 29.854 18.316 1.0018.85 1047 C TRP A 132 7.888 27.986 19.747 1.00 13.45 1048 O TRP A 1328.580 28.009 20.780 1.00 14.24 1049 OXT TRP A 132 7.328 26.956 19.3201.00 12.97 1050 OH2 WAT w 3 0.261 32.289 0.727 1.00 26.37 1051 OH2 WAT W4 18.155 41.673 14.092 1.00 22.07 1052 OH2 WAT W 5 3.066 13.691 1.1391.00 31.38 1053 OH2 WAT W 6 −2.001 26.219 10.471 1.00 17.18 1054 OH2 WATW 7 −3.962 21.533 14.199 1.00 24.79 1055 OH2 WAT W 9 −4.219 27.77210.372 1.00 22.54 1056 OH2 WAT W 10 16.168 22.783 −3.704 1.00 40.38 1057OH2 WAT W 11 9.463 12.123 32.594 1.00 26.12 1058 OH2 WAT W 15 7.51746.701 0.692 1.00 28.15 1059 OH2 WAT W 16 15.058 28.701 3.574 1.00 19.861060 OH2 WAT W 17 7.778 8.089 14.852 1.00 34.39 1061 OH2 WAT W 18 11.07129.126 20.872 1.00 14.13 1062 OH2 WAT W 21 5.925 27.933 −3.858 1.0023.69 1063 OH2 WAT W 22 17.743 35.692 1.568 1.00 23.60 1064 OH2 WAT W 237.425 8.969 12.487 1.00 35.37 1065 OH2 WAT W 24 −9.657 32.414 7.871 1.0049.96 1066 OH2 WAT W 27 −4.630 36.813 7.612 1.00 15.21 1067 OH2 WAT W 2814.275 36.488 −5.206 1.00 17.71 1068 OH2 WAT W 30 −10.848 38.870 1.9551.00 25.53 1069 OH2 WAT W 31 0.258 18.619 24.130 1.00 30.00 1070 OH2 WATW 33 20.547 24.643 16.358 1.00 38.93 1071 OH2 WAT W 34 2.932 31.091−1.203 1.00 32.87 1072 OH2 WAT W 35 13.726 13.258 31.530 1.00 16.96 1073OH2 WAT W 36 9.272 47.892 4.417 1.00 27.08 1074 OH2 WAT W 38 18.45324.784 6.373 1.00 33.48 1075 OH2 WAT W 39 16.016 33.339 −2.654 1.0021.68 1076 OH2 WAT W 40 9.305 10.547 18.786 1.00 29.41 1077 OH2 WAT W 4116.215 43.320 −0.448 1.00 21.67 1078 OH2 WAT W 43 −6.859 22.079 2.7251.00 45.81 1079 OH2 WAT W 44 1.105 13.913 2.759 1.00 37.15 1080 OH2 WATW 45 2.068 33.869 3.100 1.00 17.17 1081 OH2 WAT W 46 9.123 25.869 22.1791.00 15.32 1082 OH2 WAT W 47 14.820 31.217 2.423 1.00 19.05 1083 OH2 WATW 48 15.352 13.453 23.126 1.00 36.77 1084 OH2 WAT W 49 15.393 21.12530.136 1.00 28.18 1085 OH2 WAT W 50 10.067 35.302 −0.416 1.00 16.41 1086OH2 WAT W 52 6.479 39.660 20.953 1.00 29.28 1087 OH2 WAT W 53 3.55711.517 7.070 1.00 27.25 1088 OH2 WAT W 54 21.164 16.162 27.968 1.0032.52 1089 OH2 WAT W 55 16.536 20.422 25.510 1.00 31.71 1090 OH2 WAT W56 10.272 19.641 15.854 1.00 14.72 1091 OH2 WAT W 58 8.893 12.169 21.7301.00 31.16 1092 OH2 WAT W 59 17.216 35.031 −4.063 1.00 23.65 1093 OH2WAT W 61 13.867 22.615 28.037 1.00 27.42 1094 OH2 WAT W 62 6.823 52.63712.444 1.00 38.27 1095 OH2 WAT W 63 12.660 25.624 20.931 1.00 29.04 1096OH2 WAT W 65 9.179 19.611 18.377 1.00 12.64 1097 OH2 WAT W 66 12.78826.455 −2.296 1.00 21.40 1098 OH2 WAT W 68 1.620 13.251 10.080 1.0033.25 1099 OH2 WAT W 71 16.232 41.515 16.169 1.00 26.22 1100 OH2 WAT W74 4.087 10.020 −1.602 1.00 35.87 1101 OH2 WAT W 76 1.542 24.687 −3.4161.00 30.17 1102 OH2 WAT W 83 3.523 8.602 19.487 1.00 16.30 1103 OH2 WATW 86 11.210 46.885 3.041 1.00 26.46 1104 OH2 WAT W 87 19.040 30.0332.757 1.00 42.90 1105 OH2 WAT W 89 1.184 23.315 19.085 1.00 19.00 1106OH2 WAT W 92 12.801 45.216 9.729 1.00 21.02 1107 OH2 WAT W 93 18.29319.615 22.198 1.00 41.60 1108 OH2 WAT W 94 17.487 34.488 12.316 1.0022.73 1109 OH2 WAT W 95 −7.069 36.729 8.954 1.00 22.21 1110 OH2 WAT W 97−6.520 27.123 5.883 1.00 27.24 1111 OH2 WAT W 98 10.994 10.078 −9.5671.00 37.87 1112 OH2 WAT W 99 19.626 34.512 8.612 1.00 40.75 1113 OH2 WATW 101 1.015 16.289 25.198 1.00 15.37 1114 OH2 WAT W 102 0.276 25.49417.431 1.00 15.36 1115 OH2 WAT W 103 2.139 20.825 18.331 1.00 15.98 1116OH2 WAT W 104 16.691 34.142 8.038 1.00 17.77 1117 OH2 WAT W 105 −2.80228.998 12.507 1.00 19.40 1118 OH2 WAT W 106 6.285 25.347 −6.096 1.0020.12 1119 OH2 WAT W 107 10.723 37.111 17.353 1.00 16.57 1120 OH2 WAT W108 1.745 19.796 20.994 1.00 20.57 1121 OH2 WAT W 109 2.983 26.279−1.443 1.00 22.32 1122 OH2 WAT W 110 7.048 22.458 24.019 1.00 19.45 1123OH2 WAT W 111 −1.785 36.791 1.344 1.00 27.44 1124 OH2 WAT W 112 3.10721.974 22.207 1.00 23.19 1125 OH2 WAT W 113 −5.384 29.592 5.922 1.0020.68 1126 OH2 WAT W 114 0.554 15.364 10.840 1.00 20.38 1127 OH2 WAT W115 16.165 27.477 1.361 1.00 28.18 1128 OH2 WAT W 116 14.556 47.25010.297 1.00 22.90 1129 OH2 WAT W 117 18.154 21.823 13.453 1.00 28.481130 OH2 WAT W 118 15.610 40.135 2.416 1.00 21.57 1131 OH2 WAT W 1209.946 38.683 27.554 1.00 22.08 1132 OH2 WAT W 121 13.699 35.927 14.5231.00 21.15 1133 OH2 WAT W 122 1.632 28.671 −1.043 1.00 25.21 1134 OH2WAT W 123 14.933 14.669 18.467 1.00 22.96 1135 OH2 WAT W 124 16.73747.364 11.299 1.00 29.14 1136 OH2 WAT W 125 −3.093 19.738 7.218 1.0023.07 1137 OH2 WAT W 126 10.379 33.025 −1.744 1.00 25.17 1138 OH2 WAT W127 9.954 25.754 24.878 1.00 22.93 1139 OH2 WAT W 128 13.853 33.965−4.009 1.00 25.23 1140 OH2 WAT W 129 −0.809 29.646 0.277 1.00 24.06 1141OH2 WAT W 130 9.502 51.180 7.807 1.00 25.54 1142 OH2 WAT W 131 13.06848.612 2.146 1.00 27.48 1143 OH2 WAT W 132 14.127 42.274 0.839 1.0023.95 1144 OH2 WAT W 133 13.134 13.190 14.286 1.00 23.18 1145 OH2 WAT W134 15.159 12.904 20.597 1.00 26.16 1146 OH2 WAT W 135 10.440 23.03224.629 1.00 23.66 1147 OH2 WAT W 136 −3.713 37.445 −0.713 1.00 28.181148 OH2 WAT W 137 0.604 21.676 2.201 1.00 25.71 1149 OH2 WAT W 1381.066 37.345 −1.106 1.00 34.42 1150 OH2 WAT W 139 16.905 23.452 19.1801.00 34.87 1151 OH2 WAT W 140 4.185 36.771 20.480 1.00 40.00 1152 OH2WAT W 142 10.914 13.273 30.854 1.00 24.89 1153 OH2 WAT W 143 3.87316.101 −4.915 1.00 28.61 1154 OH2 WAT W 144 11.111 36.927 25.805 1.0025.96 1155 OH2 WAT W 145 13.608 12.384 16.901 1.00 23.49 1156 OH2 WAT W146 −0.954 11.414 −9.353 1.00 36.01 1157 OH2 WAT W 147 16.603 32.5735.264 1.00 23.66 1158 OH2 WAT W 148 12.092 41.853 23.010 1.00 25.81 1159OH2 WAT W 149 11.751 10.811 17.753 1.00 27.61 1160 OH2 WAT W 150 17.39329.734 4.814 1.00 33.79 1161 OH2 WAT W 151 16.056 33.961 14.670 1.0030.25 1162 OH2 WAT W 152 −1.210 27.071 19.148 1.00 28.86 1163 OH2 WAT W153 −6.321 36.116 11.372 1.00 33.09 1164 OH2 WAT W 154 2.148 47.68013.303 1.00 25.86 1165 OH2 WAT W 155 14.992 11.270 27.745 1.00 31.331166 OH2 WAT W 156 −1.274 22.960 20.245 1.00 29.25 1167 OH2 WAT W 1571.590 28.270 23.231 1.00 33.45 1168 OH2 WAT W 158 12.847 26.022 −7.5301.00 29.22 1169 OH2 WAT W 159 4.214 11.114 1.150 1.00 24.17 1170 OH2 WATW 160 −1.655 11.811 13.568 1.00 29.91 1171 OH2 WAT W 161 2.666 20.185−4.292 1.00 38.55 1172 OH2 WAT W 162 14.926 31.740 −1.411 1.00 28.821173 OH2 WAT W 163 15.004 47.207 13.602 1.00 42.80 1174 OH2 WAT W 16414.059 33.176 18.340 1.00 27.02 1175 OH2 WAT W 165 10.371 7.912 −3.6701.00 43.64 1176 OH2 WAT W 166 −5.215 23.809 8.874 1.00 30.82 1177 OH2WAT W 167 −1.687 21.400 0.893 1.00 32.38 1178 OH2 WAT W 168 5.863 41.99826.689 1.00 36.28 1179 OH2 WAT W 169 18.586 43.498 2.324 1.00 41.21 1180OH2 WAT W 170 9.137 22.594 27.102 1.00 27.05 1181 OH2 WAT W 171 19.82237.167 11.677 1.00 33.36 1182 OH2 WAT W 172 12.631 24.517 −4.342 1.0031.01 1183 OH2 WAT W 173 20.730 24.100 8.177 1.00 37.46 1184 OH2 WAT W174 22.422 39.621 6.823 1.00 34.02 1185 OH2 WAT W 175 3.034 33.133 0.5521.00 35.38 1186 OH2 WAT W 176 20.107 21.863 5.289 1.00 39.46 1187 OH2WAT W 177 17.163 31.964 1.388 1.00 42.30 1188 OH2 WAT W 178 12.18729.146 −3.563 1.00 31.78 1189 OH2 WAT W 179 −6.222 25.258 3.777 1.0028.97 1190 OH2 WAT W 180 12.001 47.032 13.002 1.00 29.82 1191 OH2 WAT W181 22.795 37.299 9.451 1.00 42.30 1192 OH2 WAT W 182 −7.525 30.6984.806 1.00 36.37 1193 OH2 WAT W 183 −5.215 29.584 8.649 1.00 30.25 1194OH2 WAT W 184 19.872 33.405 −4.183 1.00 36.05 1195 OH2 WAT W 185 4.74420.991 24.051 1.00 25.27 1196 OH2 WAT W 186 11.400 11.709 22.297 1.0028.93 1197 OH2 WAT W 187 −9.057 34.780 8.847 1.00 33.56 1198 OH2 WAT W188 −2.249 15.984 10.194 1.00 32.98 1199 OH2 WAT W 189 −2.884 24.95519.234 1.00 36.03 1200 OH2 WAT W 190 9.696 50.530 4.968 1.00 35.77 1201OH2 WAT W 191 21.019 30.872 11.346 1.00 38.17 1202 OH2 WAT W 192 14.20430.960 21.968 1.00 25.74 1203 OH2 WAT W 193 −7.976 32.734 3.191 1.0036.90 1204 OH2 WAT W 194 14.461 50.113 6.091 1.00 29.97 1205 OH2 WAT W195 17.801 16.321 21.589 1.00 36.20 1206 OH2 WAT W 197 18.581 44.34814.054 1.00 30.95 1207 OH2 WAT W 198 2.731 12.003 −3.103 1.00 33.47 1208OH2 WAT W 199 14.447 21.324 23.946 1.00 37.36 1209 OH2 WAT W 200 −4.23831.779 12.341 1.00 29.12 1210 OH2 WAT W 201 4.514 2.957 12.647 1.0044.36 1211 OH2 WAT W 203 0.642 19.740 3.863 1.00 38.63 1212 OH2 WAT W205 6.790 9.078 −2.562 1.00 40.08 1213 OH2 WAT W 206 4.797 31.295 −3.2501.00 33.26 1214 OH2 WAT W 207 20.687 40.871 14.582 1.00 43.83 1215 OH2WAT W 211 19.926 29.795 15.512 1.00 44.11 1216 OH2 WAT W 212 −2.67129.660 −1.627 1.00 31.81 1217 OH2 WAT W 213 15.587 48.423 3.075 1.0030.76 1218 OH2 WAT W 214 17.679 19.494 4.704 1.00 40.20 1219 OH2 WAT W215 14.957 25.819 0.027 1.00 33.37 1220 OH2 WAT W 216 15.118 34.86616.687 1.00 36.89 1221 OH2 WAT W 217 −6.271 21.840 12.594 1.00 43.411222 OH2 WAT W 218 7.913 37.111 26.296 1.00 42.81 1223 OH2 WAT W 21919.415 14.734 23.625 1.00 33.68 1224 OH2 WAT W 220 17.263 9.938 −8.6701.00 43.05 1225 OH2 WAT W 221 7.507 8.481 0.718 1.00 42.02 1226 OH2 WATW 222 12.412 51.527 8.293 1.00 39.48 1227 OH2 WAT W 223 −4.213 17.63016.081 1.00 28.56 1228 OH2 WAT W 225 13.627 8.137 6.246 1.00 45.87 1229OH2 WAT W 226 13.553 49.899 10.508 1.00 42.09 1230 OH2 WAT W 227 1.47951.259 7.651 1.00 36.49 1231 OH2 WAT W 229 −6.368 26.008 8.421 1.0035.35 1232 OH2 WAT W 230 20.435 12.355 2.203 1.00 40.09 1233 OH2 WAT W231 18.153 28.461 6.720 1.00 44.41 1234 OH2 WAT W 232 20.764 46.71510.993 1.00 47.11 1235 OH2 WAT W 233 4.419 8.228 −5.884 1.00 37.01 1236OH2 WAT W 234 −5.554 18.749 11.830 1.00 41.82 1237 OH2 WAT W 235 8.11547.714 15.867 1.00 40.18 1238 OH2 WAT W 236 6.870 26.198 25.697 1.0034.10 1239 OH2 WAT W 237 10.662 45.778 14.817 1.00 35.68 1240 OH2 WAT W238 14.400 26.566 18.363 1.00 32.18 1241 OH2 WAT W 240 3.335 45.0230.285 1.00 38.84 1242 OH2 WAT W 241 2.751 7.228 6.330 1.00 50.85 1243OH2 WAT W 242 5.710 37.994 25.220 1.00 37.91 1244 OH2 WAT W 243 20.70019.007 3.691 1.00 39.90 1245 OH2 WAT W 244 19.908 16.572 17.568 1.0056.94 1246 OH2 WAT W 246 4.431 38.416 22.728 1.00 42.21 1247 OH2 WAT W247 8.317 9.182 6.964 1.00 54.58 1248 OH2 WAT W 248 15.498 10.503 24.1161.00 46.07 1249 OH2 WAT W 249 14.443 8.663 −9.508 1.00 38.83 1250 OH2WAT W 250 0.806 46.599 2.414 1.00 38.84 1251 OH2 WAT W 251 15.869 30.18816.379 1.00 38.11 1252 OH2 WAT W 252 7.352 28.899 −6.950 1.00 66.38 1253OH2 WAT W 254 −4.943 12.924 7.071 1.00 46.90 1254 OH2 WAT W 255 −0.38920.369 25.846 1.00 34.19 1255 OH2 WAT W 256 19.975 48.181 4.575 1.0041.62 1256 OH2 WAT W 257 −3.747 29.175 −5.942 1.00 46.12 1257 OH2 WAT W258 17.067 29.492 0.012 1.00 45.57 1258 OH2 WAT W 259 −5.841 26.30511.606 1.00 44.57 1259 OH2 WAT W 261 3.022 47.371 8.159 1.00 27.51 1260OH2 WAT W 262 6.150 29.001 24.769 1.00 27.00 1261 OH2 WAT W 264 2.49249.167 6.241 1.00 31.67 1262 OH2 WAT W 265 18.777 45.611 3.013 1.0032.27 1263 OH2 WAT W 266 −11.514 36.131 7.903 1.00 33.94 1264 OH2 WAT W267 21.566 38.893 13.622 1.00 36.54 1265 OH2 WAT W 269 15.298 19.51928.683 1.00 51.15 1266 OH2 WAT W 270 19.792 27.338 15.438 1.00 41.611267 OH2 WAT W 271 15.581 11.901 13.471 1.00 33.75 1268 OH2 WAT W 27217.242 12.516 9.236 1.00 40.12 1269 OH2 WAT W 273 −6.961 15.515 12.3851.00 34.15 1270 OH2 WAT W 274 19.422 14.241 27.137 1.00 46.30 1271 OH2WAT W 283 11.632 7.314 0.873 1.00 37.15 1272 OH2 WAT W 285 3.527 24.309−6.074 1.00 37.02 1273 OH2 WAT W 286 2.752 33.234 20.239 1.00 40.00 1274OH2 WAT W 287 1.873 2.010 11.965 1.00 38.57 1275 OH2 WAT W 288 18.28430.464 10.373 1.00 44.52 1276 OH2 WAT W 289 −0.575 17.304 3.770 1.0036.81 1277 OH2 WAT W 290 −4.610 26.297 15.067 1.00 43.10 1278 OH2 WAT W291 −10.059 35.001 1.831 1.00 38.83 1279 OH2 WAT W 292 17.153 31.957−4.434 1.00 38.60 1280 OH2 WAT W 302 6.023 49.650 2.731 1.00 37.67 1281OH2 WAT W 303 21.385 13.626 28.217 1.00 35.56 1282 OH2 WAT W 304 9.96648.081 18.517 1.00 41.63 1283 OH2 WAT W 305 −1.894 34.203 −0.825 1.0041.23 1284 OH2 WAT W 306 17.745 15.877 18.835 1.00 43.82 1285 OH2 WAT W307 18.401 15.878 2.446 1.00 52.53 1286 OH2 WAT W 311 14.094 37.69817.136 1.00 42.65 1287 OH2 WAT W 312 3.354 11.493 10.405 1.00 45.24 1288OH2 WAT W 313 12.941 11.084 20.255 1.00 34.51 1289 OH2 WAT W 314 −3.49728.364 14.837 1.00 36.86 1290 OH2 WAT W 315 3.319 36.874 26.026 1.0041.44 1291 OH2 WAT W 316 13.467 27.722 20.512 1.00 43.33 1292 OH2 WAT W317 17.053 25.876 19.181 1.00 45.68 1293 OH2 WAT W 318 13.795 30.88018.217 1.00 39.19 1294 OH2 WAT W 319 −9.397 37.499 9.389 1.00 53.51 1295OH2 WAT W 321 1.652 0.597 14.057 1.00 36.90 1296 OH2 WAT W 322 −6.59830.034 −1.987 1.00 49.18 1297 OH2 WAT W 323 12.454 23.087 24.086 1.0041.19 1298 OH2 WAT W 326 16.710 42.206 1.767 1.00 64.24 1299 OH2 WAT W327 10.083 29.660 −2.635 1.00 51.02 1300 OH2 WAT W 328 −7.804 30.3929.431 1.00 39.03 1301 OH2 WAT W 330 22.466 48.916 2.705 1.00 48.85 1302OH2 WAT W 335 1.496 21.993 −2.407 1.00 38.10 1303 OH2 WAT W 336 18.28333.498 10.149 1.00 42.45 1304 OH2 WAT W 337 4.233 30.289 25.277 1.0042.76 1305 OH2 WAT W 342 24.038 47.844 0.868 1.00 39.88 1306 OH2 WAT W344 16.813 14.879 0.411 1.00 41.75 1307 OH2 WAT W 345 5.438 7.866 15.7151.00 52.84 1308 OH2 WAT W 346 16.291 23.734 −1.125 1.00 39.55 1309 OH2WAT W 347 13.025 9.450 −3.178 1.00 44.56 1310 OH2 WAT W 349 14.23322.340 2.733 1.00 50.22 1311 OH2 WAT W 350 12.227 23.367 26.694 1.0047.09 1312 OH2 WAT W 351 18.563 36.730 −4.783 1.00 64.01 1313 OH2 WAT W352 4.655 14.983 26.660 1.00 25.91 1314 OH2 WAT W 353 13.122 7.85619.736 1.00 41.94 1315 OH2 WAT W 354 −8.723 27.271 10.140 1.00 45.471316 OH2 WAT W 355 21.589 17.424 5.171 1.00 48.12 1317 OH2 WAT W 35614.998 11.204 30.356 1.00 36.89 1318 OH2 WAT W 357 −0.410 34.681 0.8101.00 41.71 1319 OH2 WAT W 358 1.781 24.032 17.043 1.00 50.64 1320 OH2WAT W 359 0.847 18.603 22.240 1.00 45.03 1321 OH2 WAT W 360 13.10536.160 −3.586 1.00 50.05 1322 OH2 WAT W 361 −0.679 20.082 20.448 1.0046.12 1323 OH2 WAT W 362 11.784 45.772 1.769 1.00 41.27 1324 OH2 WAT W363 −1.314 36.478 −0.558 1.00 45.13 1325 OH2 WAT W 364 17.040 12.29827.168 1.00 46.18 1326 OH2 WAT W 365 6.404 26.395 17.529 1.00 48.11 1327OH2 WAT W 366 13.011 50.732 13.200 1.00 39.87 1328 OH2 WAT W 367 22.71237.399 16.781 1.00 42.06 1329 OH2 WAT W 368 18.576 33.861 3.979 1.0040.44 1330 OH2 WAT W 369 1.340 17.351 −4.937 1.00 40.33

1. A composition comprising a S8 rRNA-binding protein from the smallribosomal subunit of Staphylococcus aureus in crystalline form.
 2. A S8that is derived from Staphylococcus aureus and comprising a proteinhaving the coordinates of Table 2 in an essentially pure native form ora homolog thereof.
 3. A rRNA-binding mode of the protein S8 that isderived from Staphylococcus aureus and comprising a protein having thecoordinates of Table 2 of claim
 2. 4. A rRNA-binding function accordingto claims 2 or 3 wherein said S8 protein has an rRNA-binding site formedby the amino acids 5-19 forming the N-terminal α-helix with nucleotidesA820-A885, and the surface of S8 lined by residues 4-6, 30-32, 56-57,82-92, 107-111, and 122-125 that interact with nucleotides A587-A758. 5.A heavy atom derivative of a Staphylococcus aureus S8 protein crystalwherein the rRNA-binding function comprises a protein having thecoordinates represented in FIGS. 1 and 7 to 14 and listed in Table
 2. 6.A process of identifying an inhibitor compound capable of inhibiting therRNA-binding activity of a Staphylococcus aureus S8 according to claim2, said process comprising: introducing into a suitable computer programinformation defining an rRNA-binding site conformation of a S8 inhibitorcomplex molecule comprising a conformation defined by the coordinates ofthe structures shown in FIGS. 1 and 7 to 14 and listed in Table 2wherein said program displays the three-dimensional structure thereof;creating a three dimensional structure of a test compound in saidcomputer program; displaying and superimposing the model of said testcompound on the model of said rRNA-binding site; assessing whether saidtest compound model fits spatially into the rRNA-binding site;incorporating said test compound in a biological rRNA-binding assay fora activity characterized by said rRNA-binding site; and determiningwhether said test compound inhibits binding activity in said assay.
 7. Aprocess of identifying an inhibitor compound capable of inhibiting therRNA-binding activity of a Staphylococcus aureus S8 according to claim2, said process comprising: carrying out an in vitro assay byintroducing said compound in a biological rRNA-binding assay accordingto claim 2 and determining whether said test compound inhibits theribosomal enzymatic activity or the rRNA-binding function in said assay.8. A product of the process of claim 6 that is a peptide, peptidomimeticor synthetic molecule and is useful for inhibiting the S8-rRNA bindingin the treatment of bacterial infections in a mammal.
 9. A productaccording to claim 8 wherein said product is a competitive ornon-competitive inhibitor of the Staphylococcus aureus S8-rRNA bindingactivity.
 10. A process for determining a crystal structure form usingthe structural coordinates of a Staphylococcus aureus S8 crystal orportions thereof, to determine a crystal form of a mutant, homologue orco-complex of said rRNA-binding function by molecular replacement.
 11. Aprocess designing drugs useful for inhibiting Staphylococcus aureus S8activity using the atomic coordinates of a Staphylococcus aureus S8 tocomputationally evaluate a chemical entity for associating with therRNA-binding site of a Staphylococcus aureus S8.
 12. A compositioncomprising a S8 rRNA-binding protein from the small ribosomal subunit ofStaphylococcus aureus in orthorhombic crystalline form having a spacegroup of P2₁2₁2₁.
 13. The composition according to claim 12 wherein thecrystalline form has lattice constants of a=42.1 Å, b=55.9 Å, c=61.3 Å,α=90.0°, β=90.0°, γ=90.0°.
 14. The composition according to claim 12wherein the crystalline form contains a Staphylococcus aureus S8molecule in the asymmetric unit.
 15. The composition according to claim1 wherein said S8 protein has an active site cavity formed by the aminoacids S107, T108, S109, and E126.
 16. The composition of claim 15wherein said S8 protein is characterised by the coordinates selectedfrom the group consisting of the coordinates of FIGS. 1 and 7 to 14 andTable 2.